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“Inside you vault opens behind vault endlessly. 
You will never be complete, that's how it's meant to be.” 
Tomas Tranströmer, Romanesque Arches, New Collected Poems 
  
 
  
ABSTRACT 
Background: Obesity (body mass index [BMI] ≥30 kg/m2) is associated with a range of 
physical and psychiatric comorbidities and premature mortality. Young adulthood (here 16-
25 years) constitutes a vulnerable period for weight gain, poor weight loss results, and mental 
health problems. Up to 8.3% of Swedish young adults are classified as obese. In spite of the 
fact that the peak incidence for obesity occurs during young adulthood, this age period has 
been generally overlooked in clinical obesity research, particularly in regard to obesity-
related mental health problems.  
Aim: To characterize severe obesity (BMI ≥35 kg/m2) in young adulthood (16-25 years) with 
emphasis on mental health aspects, and to study long-term outcomes (weight loss, adverse 
events, loss-to-follow-up and health-related quality of life [HRQL]) in young (18-25 years) vs 
older (≥26 years) adults after Roux-en-Y gastric bypass (RYGB). 
Methods: In Study I, we used cross-sectional self-reported questionnaire data on obesity-
related comorbidities, mental health, self-esteem, lifestyle and health-related quality of life; 
physical fitness tests; biochemical data on micronutritional deficiencies; and anthropometry 
from n=165 young adults, aged 16-25 years who were about to start treatment at the 
Karolinska University Hospital Obesity Center. In Study II, we compared cross-sectional 
questionnaire patient data (n=121 treatment-seekers to the Obesity Center, 18-25 years) on 
mental distress, self-reported suicide attempts, physical/psychosomatic symptoms, and 
quality of life with data on n=363 normal-weight responders to the Stockholm Public Health 
Cohort 2010 who were individually matched 3:1 for age, gender and socioeconomic status. 
For Studies III-IV, we frequency matched n=3,531 young (18-25 years) to n=17,137 older 
(26-74 years) patients in the Scandinavian Obesity Surgery Registry for BMI, gender and 
year of surgery to compare weight loss, adverse events, loss-to-follow-up and changes in 
HRQL between matching groups.  
Results: In Study I, we found consistent indications of poor mental and obesity-related health 
problems (up to 55%), high levels of cardiometabolic risk factors (up to 82%) and 
micronutritional deficiencies (48%) in treatment-seeking young adults (mean BMI 39.2 
kg/m2 [SD: 5.2], 80% women). In Study II, we found an increased risk of mental distress 
(adjusted relative risk [RR]=1.76, 95% CI: 1.38-2.24), suicide attempts (adjusted RR=2.04, 
95% CI: 1.06-3.95), physical/psychosomatic symptoms (adjusted RR=1.59-2.95) and poor 
quality of life (range of adjusted RR=1.97-6.61) in obese treatment-seekers (mean BMI 39.8 
kg/m2 [SD: 5.3], 81% women) compared to population controls (mean BMI 22.4 kg/m2 [SD: 
4.0], 81% women). In Study III, a total of n=369 young (37.0% of eligible) and n=2,210 older 
(46.1%) adults were followed-up 5 years after RYGB. Young adults displayed higher weight 
loss (31.8% vs 28.2%) at 5 years, more long-term adverse events (any kind of adverse events 
between 2-5 years: 20.3% vs 12.7%, adjusted OR=1.72, 95% CI: 1.29-2.31; serious adverse 
events between 2-5 years [Clavien-Dindo ≥3b]: 14.1% vs 6.9%, adjusted OR=2.06, 95% CI: 
1.45-2.92) and higher loss-to-follow-up throughout the study period (range of adjusted 
RR=1.16-2.13), all, p <0.001. In Study IV, n=138 young (20.7% of those eligible) and 
n=1,021 older (31.8%) adults were available for follow-up 5 years post-RYGB. Both young 
and older adults displayed clinically relevant improvements in physical HRQL 5 years after 
RYGB compared to baseline values, while no change or deterioration in mental HRQL was 
observed in both groups. Older adults generally experienced greater HRQL improvements 
than the young adults in adjusted analyses.  
Conclusion: Treatment-seeking young adults with severe obesity constitute a vulnerable 
patient group with a wide array of obesity-related comorbidities, particularly mental health 
issues. While we found promising weight loss results and improvements in physical HRQL in 
young adults 5 years after RYGB, there were also higher numbers of long-term adverse 
events, drop-outs and generally poor improvements in HRQL in young vs older adults. Future 
research needs to address the impact of mental distress on the development and treatment of 
obesity in young adults. Studies on the significance of and the etiology behind our data 
showing more serious adverse events and higher loss-to-follow-up in the younger RYGB-
patients are needed.  
 
Key words: Young adult, obesity, mental health, RYGB, weight loss, adverse event, loss-to-
follow-up, HRQL.  
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1 INTRODUCTION 
Obesity (body mass index [BMI] ≥30 kg/m2) is one of the major drivers behind today´s 
global burden of disease 1 2, and is estimated to account for 10-13% of deaths in the European 
region 3. Obesity may develop at any time in life, although certain age periods have been 
pinpointed as more or less vulnerable to weight gain. Young adulthood, i.e. the period 
between adolescence and independent adulthood, has been identified as one such high-risk 
period. Young adulthood constitutes the fastest weight-gaining period in life, mainly through 
the profound physiological and psychosocial changes that take place during these years 4-8. 
Notably, weight gain during young adulthood is a better predictor of cancer and mortality 
than weight gain in later adulthood 9 10.   
In 2007, a separate section for young adults (here defined as 16-25 years) with obesity was 
opened at the Obesity Center (Överviktscentrum) at the Karolinska University Hospital. The 
Obesity Center was the first, and is still the only, clinic in Sweden to provide specialized care 
for this vulnerable patient group. The specific focus on young adults with obesity is rare also 
in an international perspective. 
Throughout their clinical work, the clinicians at the Obesity Center have observed numerous 
and serious psychosocial issues among the young adult patients. Moreover, the clinicians 
were frequently faced with the major dilemma of whether young adults who displayed poor 
behavioral weight reduction should be referred for bariatric surgery. This dilemma arose 
because young adults had seldom been included in the major studies that showed health 
benefits after bariatric surgery. Given the unique traits of the young adulthood period, we 
hypothesized that we could not rely on generalization of results from adult samples. 
Despite clear findings from population cohorts on the risks of obesity in young adulthood, 
including premature mortality and an increased incidence in cardiovascular disease 11-19, we 
found that young adults had generally been overlooked in clinical obesity research compared 
to children and older adults 20. We were thus faced with a patient group at risk but without 
age-specific guidelines to refer to.  
The research questions in the present thesis emanate from the above mentioned clinical 
perceptions and were developed in collaboration with clinicians at the Obesity Center at the 
Karolinska University Hospital.  
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2 LITERATURE REVIEW  
2.1 OBESITY 
Definition 
Obesity is defined by the World Health Organization (WHO) as an excess of body adiposity 
with negative health consequences 21, and was declared a disease by the American Heart 
Association in 2013 22. The positive association between obesity and pathology was, 
however, recognized by Hippocrates as early as 400 BC when he acknowledged that 
“Corpulence is not only a disease itself, but the harbinger of others”. 
The definition of excess adiposity at the population level is based upon BMI (weight [kg] 
divided by height [m]2), and is defined as BMI ≥30 kg/m2 in adults, while the cut-off in <18 
year-olds, is at plus two standard deviations of BMI for age and sex  21 23 24. BMI displays a J-
shaped association with all-cause mortality 25, and obesity is classified into class I (30.0-34.9 
kg/m2) , class II (35.0-39.9 kg/m2) and class III (≥40.0 kg/m2) obesity 26. BMI ≥35 kg/m2 is 
defined as severe obesity. At an individual level, BMI may inaccurately assess excess 
adiposity since skeletal muscle mass is not taken into account in the BMI calculation. 
Moreover, fat distribution (central/peripheral fat deposits) is more strongly associated with 
obesity-related morbidity than BMI 27, and ethnic- and age-dependent variations in BMI-
related comorbidities exist 28 29, which together further complicate the applicability of BMI. 
Despite the above-mentioned limitations, the concept of BMI is generally used in clinical 
work, while more precise measurements of adiposity such as magnetic resonance scanning 
are not applicable in a clinical setting given the high frequency of obesity in today’s society.  
Obesity is increasing worldwide with no signs of levelling off. Globally, the prevalence has 
nearly doubled compared to 1980 5. In total, 12% of adults and 5% of children worldwide are 
classified as obese 5. The peak prevalence for obesity is 60-64 years among women, and 50-
54 years among men 5. In Sweden, 15% of Swedish 16- to 84-year-old men and women were 
classified as obese in 2016 according to self-reported data, indicating an increase from 11% 
in 2011 30. According to a study from 2008 31, the cost of obesity in Sweden totals SEK 3,600 
million (equivalent to 1.9% of the Swedish Gross Domestic Product) spent on health care.  
Pathogenesis 
Obesity is a consequence of the individual’s susceptibility to environmental triggers that lead 
to caloric overconsumption relative to his/her bodily needs in terms of activity level and 
metabolism 32. Why calories may supersede need is suggested to largely be a consequence of 
ingested calories per se, rather than due to differences in calorie activity depending on dietary 
source 33 34. Energy homeostasis is delicately controlled by neurohormonal inner pathways in 
concordance with external signals that trigger hunger, and satiety signals to defend against 
weight change irrespective of present weight (set-point theory) 35-37.  
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External signals include the changing global food environment and an increased availability 
and affordability of energy-dense nutrition in the last 40 years, which is proposed to account 
for the recent sharp rise in incidence and prevalence of obesity 38. Conflicting evidence exists 
as to what degree decreased physical activity actually contributes to the upshift in energy 
homeostasis given that the major change in decreased energy output occurred before the rise 
in the obesity epidemic 39 . Instead, physical activity is suggested to play a significant role in 
weight maintenance and regulation in calorie intake, rather than by direct contribution to 
caloric imbalance per se 40.   
Other external factors such as endocrine disruptors, infections, ambient temperature and 
antibiotics are suggested to change and disturb the internal homeostasis, thereby contributing 
to long-term energy storage surplus 41-43, via for example hypothalamic inflammation 44 45. 
Moreover, behavioral factors including sleep deprivation, smoking cessation and time 
discounting are also suggested to play a role in flipping the energy homeostasis and thereby 
impacting on weight status 46-48. Importantly, there is a strong association between obesity 
and socioeconomic status, with a positive association in developing countries and an inverse 
relationship in developed countries (applies to both children and adults), although the exact 
mechanisms for this are still to be revealed 49-51.  
The recent steep rise in obesity prevalence supports a multifactorial pathogenesis, rather than 
a single gene, as the causative agent in creating a positive energy balance and ultimately 
obesity. Single identifiable obesity-prone genetic mutations are rare 52, but studies on 
monogenetic twins display around 70% concordance on fat mass and dizygotic twins display 
around 32% concordance 53, together supporting a partly genetic etiology of obesity. 
Hereditary traits may predispose to obesity via external triggers and effects on hunger, satiety 
and food intake 53. For example, a certain gene polymorphism may predispose to food 
palatability, eating for reasons other than hunger, and physical activity dependent effects on 
weight 54.   
Once obesity has manifested in an individual, compensatory processes counteract weight 
loss, thereby favoring long-term excess adiposity (the set-point theory) 36 37 55. Here, 
hormonal responses, such as leptin deficiency and the recently launched theory of an 
osteocyte pathway are suggested to contribute 56 57. Considering these modern theories of 
obesity pathogenesis, obesity is today regarded as a two-stage disease: one step with a 
sustained positive energy balance (accumulation of fat mass), and another that resets the body 
weight set-point at a higher-than-before value (maintaining fat mass) 33. Which of these two 
stages come first is, however, part of current research discussion. 
Given the multifactorial pathogenesis of obesity, obesity was recently reevaluated as having a 
common phenotype with heterogeneous etiologies, rather than the previously prevailing 
“one-disease” approach 58. Possibly, this new perspective on obesity may clarify the differing 
roles of genetics, demographics and life style in the pathogenesis of excess adiposity. 
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Obesity-related mortality and morbidity 
Obesity is clearly associated with low quality of life 59, and physical, psychiatric as well as 
social consequences of obesity may contribute to limitations in everyday life:  
Obesity is associated with premature mortality according to repeated pooled, prospective 
studies, and cardiovascular diseases constitute the major part of obesity-related mortality and 
morbidity 25 60-62. Diabetes mellitus type 2 (T2DM) was identified as the second leading cause 
of obesity-associated mortality, while chronic kidney disease was identified as the second 
leading cause of obesity-associated morbidity 5 63.  
Cancer incidence has been positively associated with BMI according to several meta-analyses 
64-66 with relative risks (RR) of 1.2-1.5 for each 5 kg/m2 increase in BMI when compared to 
the risk in normal weight individuals (esophageal, breast, renal, thyroid, colon and 
endometrial cancer) 64.  
Besides cardiovascular diseases and cancer, obesity-related diseases include osteoarthritis, 
infertility, polycystic ovary syndrome, sleep apnea, anxiety and depression among others 67-69. 
Despite clear associations between obesity and the above-mentioned 
disorders/symptomatologies at a population level, obesity must be viewed as a highly 
heterogeneous disorder in individual patients because specific BMI levels are by no means 
directly correlated to disease levels. Instead, obesity-related comorbidities are suggested to be 
conditioned on visceral/peripheral fat, adiposopathy, physical activity levels and nutritional 
quality, rather than body weight per se 27.   
Obesity treatment: Behavioral weight reduction, pharmacotherapy and bariatric 
surgery  
Obesity treatment aims to provide the patients with strategies to reduce their total caloric 
surplus, either by lifestyle interventions, low-calorie diets, pharmacological treatments and/or 
bariatric surgery. Weight loss ≥5% is considered to affect physical health in a clinically 
positive way 70. 
Behavioral weight reduction and low-calorie diets 
Sustained life style interventions, i.e. lowering caloric intake and increasing energy output, 
may together lead to weight loss 71 72, although the variability between individuals is large 58.  
Intensive support and monitoring are proven to sustain 5% weight loss up to 8 years after 
intervention 72. Notably, no difference in long-term weight loss has been observed between 
different kinds of diet regimens 73 74, and recent research failed to demonstrate positive 
associations for interactions between genes, insulin secretion or effects of certain dietary 
compositions 34.  
Besides weight loss, (intensive) lifestyle interventions displayed other positive side effects on 
health such as improved cardiovascular biomarkers, reduced incidence of T2DM and lower 
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liver fat, depression rates, urinary incontinence, knee pain, sleep apnea and need for 
antidiabetic medications (from the Look AHEAD and Diabetes Prevention Program studies) 
among others 71 75-80.  
Lifestyle interventions may also be supplemented by low or very low calorie diets, which, 
according to a meta-analysis resulted in 5.0-6.3% weight loss at a mean of 1.9 years after 
completing the low calorie diet 81. 
Pharmacotherapy 
Three anti-obesity drugs have been approved in Sweden for patients with BMI ≥30 kg/m2 or 
BMI ≥27 kg/m2 together with obesity-related comorbidities: orlistat, naltrexone/bupropion 
and liraglutide.  
Orlistat (launched in 1999) acts by inhibiting pancreatic lipase, whereby the uptake of fatty 
acids is reduced by 30%. The total weight reduction is about 10.2% after 1 year if combined 
with lifestyle interventions (vs 6.2% in placebo group); patients on Orlistat regained less 
weight during year 2 and also showed higher reductions in cardiometabolic risk markers than 
patients who switched to placebo 82.  
Recently, two new anti-obesity agents were approved in Sweden: 1) the combined pill with 
naltrexone/bupropion, and 2) liraglutide. Naltrexon is an opioid receptor antagonist, while 
bupropion is a dopamine/norepinephrine reuptake inhibitor, together giving sustained 
decrease in appetite. The average weight loss for patients on naltrexone/bupropion was 9.3% 
compared to 5.1% on placebo 83, and a HbA1c-level ≤7.0 was reached in 44.1% (on 
naltrexone/bupropion) vs 26.3% on placebo after 56 weeks 84.  
Liraglutide is a GLP-1 analogue, which acts via neuronal pathways to slow down gastric 
emptying and increase satiety 85. At 56 weeks, weight loss was 5.8 kg more for patients on 
liraglutide vs placebo, and 3.8 kg more than those on Orlistat. Furthermore, blood pressure 
and the prevalence of metabolic syndrome and prediabetes were lower in the active treatment 
group 86. All-cause mortality has been proven reduced in patients on Liraglutide compared to 
placebo (HR [hazard ratio] =0.85, 95% CI [confidence interval]: 0.74-0.97) 87. 
Combined interventions with medications and lifestyle changes demonstrate more weight loss 
compared to medication or lifestyle changes alone 88. However, discontinuation of 
pharmacological treatment is common in real-life settings 89 and novel pharmacological anti-
obesity agents are continuously needed.  
Bariatric surgery  
Bariatric surgery is without comparison the most efficient weight loss strategy to date 90-93. 
Criteria for bariatric surgery in Sweden varies throughout the country secondary to local 
obesity guidelines and diverse economical compensation schemes. However, a majority of 
surgical centers apply the following criteria for bariatric surgery: BMI ≥35 kg/m2, age ≥18 
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years, previous adherence to weight loss strategies, stable psychosocial situation and high 
motivation to undergo life style changes associated with bariatric surgery. 
Bariatric surgery includes any technique that reduces the stomach size by changing the 
anatomy (gastric bypass [GBP], gastric sleeve, biliopancreatic diversion with duodenal 
switch) or by inserting a restrictive band into the ventricle (gastric banding). The present 
thesis includes studies (Studies III-IV) on GBP which accounts for 64% of surgical 
interventions in Sweden (2016) 94. In total, 5,500 surgical interventions were performed in 
Sweden in 2016 (irrespective of mode of surgery), and numbers are decreasing from the peak 
of 9,000 surgical interventions/year in 2011 94. 
Gastric bypass 
Surgical techniques  
In GBP, the stomach is stapled and reduced into a pouch, leading to restriction of food intake. 
The pouch is connected to the jejunum, thereby by-passing the upper small intestine, which 
results in malabsorption and secondary weight loss. Roux-en-Y gastric bypass (RYGB) is the 
most common variant of GBP and the GBP-modality of choice in Sweden. In RYGB, the 
small intestine is divided 45 cm below the lower stomach outlet and formed into an Y-
configuration, allowing the contents from the small pouch to drain into the upper part of the 
small intestine, thereby enabling uptake of nutrients along the passage of most of the small 
intestine. Close to 100% of the RYGBs in Sweden are performed using the antecolic, 
antegastric technique according to Lönroth et al 95. 
Positive effects 
When developed, GBP was assumed to lead to weight loss mainly through mechanical 
malabsorption and a faster transition of ingested food. However, research found that 
modifiers of neurohormonal circuits, including gut hormones, bile acids, vagal signaling and 
intestinal microbiota appeared to account for the main weight loss 96-98. Moreover, the 
physiologic complication of dumping syndrome causes weight loss post-GBP via 
gastrointestinal and vasomotor symptoms secondary to an osmotic shift of fluids from the 
intravascular compartments into the intestines after food intake 99.   
Meta-analyses display a mean weight loss after GBP in adults with BMI ≥40 kg/m2 of 20-30 
kg up to 10 years after surgery 93. Mortality (OR=0.48, 95% CI: 0.35-0.64), cardiovascular 
adverse events (OR=0.54, 95% CI: 0.41-0.70), myocardial infarction (OR=0.46, 95% CI: 
0.30-0.69) and stroke (OR=0.49, 95% CI: 0.32-0.75) were all reduced compared to non-
surgical controls in meta-analyses with follow-up data up to 14 years after bariatric surgery 
100. In a recent randomized controlled trial (RCT) of patients from a 2-year lifestyle-intensive 
intervention program with/without RYGB, 23% of surgery patients compared to 4% of non-
surgery patients had achieved the endpoint of HbA1c ≤7.0%, low-density lipoprotein 
cholesterol ≤100 mg/Dl and systolic blood pressure below 130 mm hg (as recommended by 
the American Diabetes Association) 5 years after surgery 101.  A comparison of patients with 
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severe obesity on either surgical treatment or specialized medical treatment displayed 
favorable 6.5-year data for the surgically treated with a greater likelihood of remission of 
hypertension (RR=2.1, 95% CI: 2.0-2.2) and diabetes (RR=3.9, 95% CI: 2.8-5.4) 102. Micro- 
(HR=0.44, 95% CI: 0.34-0.56) and macrovascular (HR=0.64, 95% CI: 0.54-0.85) 
complications of T2DM as well as cancer incidence (only in women, HR=0.58, 95% CI: 
0.44-0.77) were also reduced in GBP patients compared to obese controls (Swedish Obese 
Subjects Study [SOS]) 103 104.  
Positive effects of bariatric surgery were also seen for pregnancy outcomes in Swedish 
registry studies, such as a reduced risk of gestational diabetes and excessive fetal growth 105. 
However, gestation was shorter and there was an increased risk of small-for-gestational-age 
after bariatric surgery vs population controls 105.  
Nonetheless, diminishing effects over time warrant longer follow-ups 101. Data on healthcare 
costs and utilization after bariatric surgery revealed both net savings compared to non-
bariatric samples 91 and short-term increases in total expenditures, while long-term drug 
expenditures were lower for the surgically vs non-surgically treated obese patient group 106.  
Negative side effects 
Albeit the obvious positive effects on weight loss and resolution of comorbidities, the 
negative side effects of GBP must be mentioned: Mortality after GBP is low in Sweden, 
estimated to 0.05% within 30 days after surgery 107. Short-term (within 6 weeks of surgery) 
adverse events (any kind, see below) occur in about 6% of operations, and serious short-term 
adverse events (grade ≥3b according to the Clavien-Dindo classification 108) occur in about 
3% of operations 94. Short-term adverse events are primarily related to intraoperative factors 
or perioperative care and include leakages from any of the anastomoses or the small bowel 
(1.8% of GBP-patients), staple line bleeding (2.1%), wound dehiscence (0.1%), small bowel 
obstructions due to edema for example, bleeding clot, stenosis or ischemia (1.0%), stricture 
(0.2%), ulcer (0.5%), venous thromboembolism (0.1%), cardiovascular complications 
(0.2%), pulmonary complications (0.7%) and urinary tract infections (0.4%) 109. Long-term 
adverse events between 6 weeks and 5 years affected 13.2% of patients, including perforation 
(0.2% of patients), bowel obstruction due to internal hernia, adhesion, anastomotic stricture 
and intussusception (5.2%); wound dehiscence (1.3%) and ulcer (1.8%) according to Swedish 
registry data 94. The risk of long-term incisional hernia clearly diminished after the 
introduction of laparoscopic techniques, although the overall rate of complications was not 
affected 110.  
Lately, the issue of chronic abdominal pain post-RYGB has been highlighted 111, which 
affects about one third of patients. Besides surgical side effects, there are rising concerns 
about psychiatric adverse events, including problematic use of alcohol (HR=2.3, 95% CI: 1.7-
3.2 for before vs after surgery) and increased prescription of psychotropic medication and 
opioids (RR=1.3, 95% CI: 1.2-1.4 for surgery vs medical intensive therapy), which might 
be secondary to the augmented risk for post-surgical chronic abdominal pain 102 111-115. In a 
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recent Swedish registry study, the HRs  for alcohol abuse (HR=2.7, 95% CI: 2.4-3.2), other 
substance use disorders (HR=3.2, 95% 2.5-4.0), depression (HR=3.2, 95% CI: 2.8-3.7) and 
suicide attempt (HR=2.9, 95% CI: 2.4-3.4) in a GBP cohort compared to the reference 
population during a follow-up period of up to 8.6 years, call for attention 113. Likewise, the 
GBP cohort displayed increased risks for all of the above-mentioned diagnoses (incidence 
rate ratios [IRR] of 2.6-7.7) after surgery, while the control group displayed increased IRR 
only for alcohol abuse, other substance use disorders and depression (IRR=1.4-2.3). In 
another nationwide Swedish registry cohort of GBP patients, a diagnosis of depression prior 
to surgery displayed a HR of 52.3 (95% CI: 30.6-89.2) for depression after surgery compared 
to GBP patients without depression before surgery 114. Similarly, self-harm prior to surgery 
displayed a HR of 36.6 (95% CI: 25.5-52.4) for self-harm after surgery compared to patients 
with no history of self-harm 114. Faster absorption and a higher peak in ethanol concentration 
post-RYGB is suggested to account for the increased risk of alcohol abuse after bariatric 
surgery 116 and may, hypothetically, also impact on post-surgical suicide rates. Meanwhile, 
discontinuation of medications, lower absorption of psychotropic medications post-surgery, 
inadequate weight loss and changes in the release of gut hormones may explain the etiology 
behind other psychiatric side effects 117. The question of whether increasing psychiatric 
adverse events are a direct result of surgery or are cohort effects, remains to be answered. 
Together, the lower absorption of nutrients and bypassing the acid-producing part of the 
ventricle, clearly increases the risk of malnutrition, notably iron, vitamin B12 and vitamin D 
deficiency 118. Supplementation pre-surgery in accordance with the Nordic guidelines, and 
continuous yearly monitoring is therefore essential 119.  
In conclusion, GBP is considered a generally safe procedure, and for the average morbidly 
obese patient, the health risks associated with obesity outweigh the risks of surgery 120. 
However, as accounted for above, a number of long-term unexpected side effects have 
emerged. A careful evaluation of benefits as well as potential harmful side effects at the 
individual patient level is increasingly necessary as more side effects are being discovered.  
 
2.2 YOUNG ADULTHOOD 
- The transition from adolescence to independent adulthood 
Young adulthood has recently gained attention as a period of unique medical value in regard 
to physiological and sociological changes, which differentiate it from adolescence and older 
adulthood. Neurologically, young adulthood includes developments in limbic structures and 
the prefrontal cortex that favor changes in pleasure seeking and affect emotional regulation, 
sleep patterns, reward-seeking behavior (which promote risk-taking) as well as advancements 
in abstract and logical thinking, decision-making, impulse control and future planning 121. 
Socially, young adulthood is a period of transition from dependence to independence; from 
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living with family members and going to school, to building a household, achieving self-
sufficiency and becoming a responsible citizen, i.e. markers that define adulthood 122-124.   
Definitions of young adulthood 
The question of whether young adulthood is a distinct developmental period, such as 
adolescence, is under continuous debate because the above-mentioned social patterns do not 
appear globally. Accordingly, the years in between adolescence and independent adulthood 
are defined by different terms and age spans depending on setting. Contemporary definitions 
include the following: 
 WHO defines “adolescence” as 10 to 19 years old, and “youth” as 15 to 24 years old 
125.  
 United Nations defines “youth” as a “period of transition from dependence of 
childhood to adulthood’s independence and awareness of our interdependence as 
members of a community”, defined chronologically as the period between 15 and 24 
years 126. 
 The Swedish Public Health Authority (Folkhälsomyndigheten) defines youth as 14 to 
19 years old and young adults as 20 to 29 years old 127. 
 The Stockholm County Council defines young adults as 16 to 25 years old. 
 In research, terms such as youth, young adults, emerging adults and early adults are 
used interchangeably.  
In this thesis, the terms “young adult / young adulthood” were chosen due to the initial 
request from the Stockholm County Council to the Obesity Center to provide “specialized 
obesity treatment for young adults (16-25 years)”.  
Young adults in the western 21st century 
- Social and medical challenges 
The transition to adulthood in modern western society is considered to be prolonged due to 
shifting social norms and economic realities, including economic hardship and higher 
unemployment rates among uneducated youth in particular 128. Likewise, increasing numbers 
of young people pursue university education and thereby postpone a financially independent 
adult life 129 130. Secondary delays in partnership and parenthood combined with an 
acceptance of prolonged individual freedom adjourn what is traditionally seen as independent 
adult life.  
Previous views of young adults as being free from disease are shifting and becoming more 
nuanced. In this respect, the “Lancet Commission on Adolescent Health and Wellbeing” 
(2016) recently stated that young adults have been largely neglected in welfare systems and 
society compared to children and older adults 131. 
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According to a WHO study of 50 countries, the health of young adults improved only half as 
much as for younger children, mainly due to road and work-related injuries 132. The 
distribution of young adults’ health hazards is changing, with a growing number of chronic 
diseases due to higher survival rates from childhood and a higher incidence of metabolic 
cardiovascular diseases (e.g. obesity-related comorbidities) at younger ages. In Sweden, 
mortality in the 15 to 29 years age group has remained constant since the middle of the 
1990s, whereas mortality has been decreasing in all other age groups 133.  
Swedish healthcare statistics as well as national questionnaires reveal an increasingly higher 
prevalence of mental health problems in Swedish young adults since the 1990s; particularly 
among women, immigrants and individuals with low socioeconomic resources 134-136. 
Anxiety, depressive and substance abuse disorders account for the main rise in mental illness 
prevalence 135. Importantly, young adults constitute the only age group in Sweden that did not 
experience a decrease in numbers of committed suicides since 1980 137, and the peak 
incidence of mental illnesses takes place during young adulthood 138. High unemployment 
rates among young adults has been discussed as one explanation behind the increasing rates 
of mental health issues in this age group 139 140.  
Possibly, the failed transition of healthcare for adolescents with chronic diseases to adult 
healthcare is partly to blame for the poor health outcomes described above 141. The young 
adult’s risk-taking behavior and tendency to challenge authorities have been discussed as 
possible mechanisms behind such failures of care continuity between age groups 142. 
Young adulthood - a critical period for the development of obesity 
As shown in Figure 1, young adulthood has been highlighted as a critical period for the 
development of obesity 4 5 20 143 144.  
In the westernized world, 8.3% of women and 8.9% of men aged 15-19 years, and 13.2% of 
women and 12.2% of men aged 20-24 years were classified as obese in 2013 (extracted data, 
Figure 1) 4. In Swedish self-reported data, 3.5% of women and 3.0% of men aged 16-19 
years, and 8.3% of women and 7.7% of men aged 20-24 years were classified as obese in 
2015 145. Obesity in Swedish young adults increased almost 175% between 2002 and 2010 
(self-reported data) 146. In Stockholm, 3% of 18-24-year-old men and women had a BMI ≥30 
kg/m2 in 2015, which is a statistically significant reduction compared to 5% in 2011 147. BMI 
trajectories from childhood into young adulthood demonstrate that obesity in early childhood 
and adolescence clearly predicts obesity in young adulthood 148-150. Likewise, obesity in 
young adulthood clearly predicts obesity in later adult life 151.  
Physiologically, the surge in obesity incidence may be explained by increased total body fat 
and decreased insulin sensitivity secondary to the influx of sex and growth hormones during 
adolescence 152-155. Child-bearing puts young adult women at further risk of weight gain 156.  
Alongside physiological contributors, young adults’ changing social habitats are believed to 
influence weight status: Critical life points such as leaving home, starting university or a job 
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career may predispose to obesity-prone behavior due to for example monetary deficiencies, 
poor cooking skills and an urge for independency expressed via new (unhealthy) life style 
behaviors 20 144 157-160. Declining rates of eating together as a family and home-cooking may 
leave the young adult without skills to prepare their own meals, leading to frequent eating-out 
20 157 161 162. Moreover, the young adults’ urge to lead an independent life is the target of fast 
food and soft drink marketing 20. The declining rates of physical activity seen throughout the 
late teens may also promote the development of obesity 144 163. Herein, recent data reported 
that Swedish young adults are more sedentary in every-day life than elderly  ≥85 years 164. 
Moreover, social norms tend to be important health determinants, in particular in young 
adults 165, and adolescent body dissatisfaction with secondary dieting and dietary restraint 
have been associated with obesity development in later adolescence 166. In addition, weight-
teasing and parental weight-related concerns are associated with increasing weight in young 
adulthood 167.  
 
 
Figure 1. Prevalence of overweight and obesity and obesity alone, by age and sex, 2013. Reprinted with 
permission. Ng M et al. Lancet 2014; 284(9945):766-81 
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Physical, mental and social consequences of obesity in young adulthood 
Physical comorbidities 
Obesity-related cardiovascular comorbidities are generally not yet present in young adulthood 
168, although abnormal levels of cardiovascular markers may exist 169-172. Other obesity-
related health problems such as polycystic ovary syndrome 173, stress urinary incontinence in 
midlife 174 and functional limitations 175 are positively associated with BMI in this age group, 
and young adults with obesity rate their general health worse than their normal weight 
counterparts (OR=4.5, 95% CI: 2.9-7.0) 176.  
Prospective longitudinal studies (Harvard Growth Study 14, Swedish conscription data 15, 
Danish conscription data 16, US National Health Interview Survey 19, national Israeli data 18 
177) found an approximately doubled to tripled risk of all-cause mortality in later adulthood if 
overweight/obese in adolescence/young adulthood compared to if normal weight.  
Moreover, longitudinal data display a positive association between obesity in young 
adulthood and future risk for fatty liver disease, metabolic syndrome, and T2DM, irrespective 
of metabolic disturbances at baseline 12 178, and a recent Swedish study displayed a positive 
association between BMI in young men (conscription data) and future adult heart failure with 
a HR=9.2, 95% CI: 6.6-12.9, if BMI ≥35 kg/m2 compared to those with normal weight at 
baseline 11.  
Concerning health risks associated with weight gain in young adulthood, the comprehensive 
American CARDIA study (the Coronary Artery Risk Development in Young Adult Study) 
reported that young adults with changing BMI displayed a progression of metabolic risk 
markers, while young adults with stable BMI levels had minimal progression regardless of 
baseline BMI 179. Likewise, young adults who continuously gained weight displayed an 
increased risk of future cardiovascular disease, independently of initial weight status. In 
contrast, initially overweight (BMI: 25.0-29.9 kg/m2) displayed higher levels of risk factors 
compared to initially normal weight 180.  
Mental health  
Existing studies on coexisting obesity and mental health problems primarily included mood 
disorders, and research was mainly conducted on community samples or clinical cohorts with 
bariatric surgery patients.  
Cross-sectional community studies display both positive (range of odds ratio [OR]: 1.0-2.6) 
181-190 and no 176 187 191-195 or inverse 196 associations between obesity and mood disorders or 
BMI and depressive symptoms in young adults/adolescents. A few studies displayed positive 
associations in men 197 198 or women 183 187 only.  
In treatment-seeking, non-bariatric patients, the only cross-sectional study on mental health 
prior to this thesis found a higher prevalence of mood disorders in German patients with 
obesity (mean BMI 42.4 kg/m2) compared to their population counterparts (mean BMI 29.8 
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kg/m2, 43% vs 17%). However, generalization of results is limited due to a low participation 
rate (n=47), no adjustment for covariates and diverging BMI levels between patients and 
population controls 199.  
In bariatric cohorts, young adults were included in studies primarily aimed at studying 
adolescents (i.e. <18 years of age), and results have seldom been stratified by age groups. A 
systematic review of psychosocial status in adolescent candidates for bariatric surgery found 
that 30-68% of candidates had moderate to severe depression and 25% had an anxiety 
disorder 200.  
Concerning bidirectional, longitudinal associations of obesity and mood disorders (largely 
population studies), some studies on mood disorders in adolescence/young adulthood and 
subsequent weight gain and/or obesity (up to late adulthood) found a positive association 
(range of OR=1.5-3.8) 195 201-206, while others found an inverse 207 (B=-0.38 in CES-D score 
vs BMI level) or no 176 187 208-211 association. A few studies found positive associations only in 
previously overweight, but negative associations in previously lean 212. A systematic review 
of depression in childhood/adolescence (age 6-19) and obesity later in life displayed ORs of 
1.9-3.5 with 95% confidence intervals varying between 1.0 and 5.8 213.  
A number of studies on longitudinal associations on obesity and mood disorders found 
significantly different results between genders with positive associations in females but not in 
males 195 201 203 205 206, while one study found contrasting results with a positive association in 
males only 207. 
Longitudinal studies on obesity in adolescence/young adulthood and mood 
disorders/depressive symptoms later in life also displayed mixed results with positive 188 195 
214-217 (range of OR=1.3-5.9) no 187 191 218 219 or inverse (each 5-kg/m2 increase in BMI, 
decreased the risk of suicide by 15%) 220 associations. In a meta-analysis of longitudinal 
associations between obesity at baseline and depressive disorder at follow-up, which covered 
all ages, the odds for depressive disorders at follow-up were higher in <20 year olds 
compared with older participants (OR=1.7 vs. 1.3) 67. A few studies displayed positive 
associations in females only 195 217 221. 
In summary, previous research suggests that comorbid mood disorders and obesity clearly 
exist in young adults, although the associations are far from clear. The mixed results between 
studies may be secondary to failures of defining subtypes of mood disorders, given that some 
subtypes are suggested to be associated with underweight (melancholic depression), while 
others are associated with overweight (atypical depression, juvenile onset depression) 182 222. 
Generally, comparison of results on comorbid obesity and mood distress/disorders in young 
adults was limited due to heterogeneous use of measurements of obesity as well as mental 
health. The community studies enrolled few participants with obesity (compared to numbers 
of normal weight) and, frequently, a distinction between underweight and normal weight 
participants was lacking 223.  
  15 
Shared biological and lifestyle modifying pathways, weight gain secondary to negative side 
effects of antidepressant treatment, peer victimization, inaccurate weight perception, shame 
and binge eating have been discussed as possible explanatory factors for why obesity and 
mental distress co-occur in adolescence/young adulthood 224. Moreover, since obesity and 
mood disorders are both common states, they may co-occur by chance alone, as discussed by 
McElroy et al 222. 
Concerning mental health problems other than mood disorders, obesity in young adulthood 
has been positively associated with childhood attention deficit hyperactivity disorder 
(ADHD) and behavioral problems 225-227, while no clear associations have been found 
between obesity and later schizophrenia 228.  
Social consequences 
Socioeconomic hazards of obesity on the individual level in young adulthood have primarily 
been described by Gortmaker et al, who clearly showed that individuals who were classified 
as obese in adolescence were less likely to get married, had lower household incomes and 
fewer years of education in young adulthood, irrespective of baseline socioeconomic status 
229. Negative stereotypes of obese students as being lazy, societal discrimination and parental 
weight stigmatization have been discussed as possible explanations 230 231.   
Weight management in young adults 
Behavioral weight reduction programs have displayed poor results and/or shorter weight loss 
maintenance in young compared to older adults 232-234. Given the specific traits of young 
adults as described above, including difficulties with planning, an urge to be “disease-free” 
and frequently moving houses, it is not surprising that traditional weight reduction programs 
fail. However, the fact that young adulthood is a period of changing habits, may also be used 
as an opportunity to empower the young adult to start adhering to a healthier lifestyle. 
Research has found that young adults’ motivation to seek and stay in obesity treatment differs 
from that of older adults, and that traditional obesity treatment seldom has accounted for such 
differences 233 234.  For example, social appearance was an important motivator in young 
adults, while older adults pursued weight loss to achieve health benefits 234.  
Evidence on young adults’ performance in weight reduction is, however, limited. Attrition, 
and difficulties in attracting young adults to trials, are general obstacles to reliable results in 
the young adult age group in obesity research, as well as in other medical fields. 235-237.  
A systematic review of 14 behavioral weight loss trials in young adults displayed 3.0 kg 
weight loss (95% CI: 1.5-4.4) (up to 52 weeks of follow-up) 235, and the only significant 
change in risk factors was an improvement in HDL cholesterol 235.  
Likewise, young adults have seldom been included in bariatric surgery trials and/or results 
have generally not been stratified by 18-to-25-year-olds. Consequently, long-term results are 
lacking, and outcomes besides weight loss have rarely been reported. Lennerz et al provided 
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2-year results on n=47 18-to-21-year-olds and reported -16.2 BMI units weight loss along 
with reductions in comorbidities such as T2DM and hypertension 236. For comparison, the 
Swedish Adolescent Morbid Obesity Surgery Study (AMOS) on n=81, 13-to-18-year-olds 
with a mean BMI of 45.5 kg/m2 found significant weight loss (-13.1 BMI units), normalized 
glucose homeostasis (81%), remission of T2DM (in 3/3 patients), normalized blood pressure 
(100%) and normalized aspartate aminotransferase levels (100%) 5 years after RYGB 238. 
However, after 5 years, 25% of surgical patients had undergone additional abdominal 
surgery, 72% displayed a micronutritional deficiency and they had consumed more healthcare 
than adolescent non-surgical controls with obesity 238.  
Concerning side effects of bariatric surgery in young cohorts, a recent study found that 
externally caused mortality was higher for patients <35 years undergoing bariatric surgery vs 
severely obese in conservative treatment (HR=2.53, 95% CI: 1.27-5.07) 239, possibly caused 
by suicide as discussed above. Young age was also associated with an increased risk of 
problematic alcohol use after surgery 115. Moreover, Zeller et al followed n=14 adolescents 
after bariatric surgery into young adulthood, whereof n=11 presented with pre-surgery mental 
health symptoms outside the normal range 240. Post-surgery, mental health trajectories varied 
greatly between individuals with n=5 out of n=11 displaying remission and n=6 displaying 
persistent symptomatology, while no new cases of poor mental health were observed 240.  
Given young adults’ low adherence to medical treatments in general, obesity professionals 
express concerns about young adults, in particular in regard to adherence to vitamin 
supplementation after surgery. This has, however, not yet been thoroughly investigated.   
 
2.3 GAPS IN KNOWLEDGE 
Firstly, parts of the reviewed literature were based on adolescent research as data on young 
adults were lacking. Obviously, this lack clearly highlights a general need for young adult 
data in order to evaluate whether and how young adults with obesity differ from their younger 
and older counterparts. This method of reasoning is, however, based on the assumption that 
young adulthood per definition is a unique age period with specific needs.  
The knowledge base of young adults with obesity is generally based on community samples, 
which may differ from clinical cohorts, and generalization of results from community settings 
to clinical cohorts may not be applicable 241.  
Notably, young adults are pushed towards bariatric surgery due to poor results in behavioral 
treatment despite the fact that results of surgery in the young are yet to be published. 
Finally, there is a relative mismatch of research on physical vs psychiatric comorbidities in 
young adults with obesity, given that the incidence of mental illness peaks at 25 years, and 
that worrying tendencies of serious psychiatric adverse events including alcohol abuse after 
bariatric surgery in younger cohorts in particular have been observed.  
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3 AIMS AND RESEARCH QUESTIONS 
3.1 OVERALL AIM 
The overall aim of the thesis was to enhance the knowledge on treatment-seeking young 
adults with severe obesity concerning comorbidities and treatment outcomes in order to 
improve clinical decision-making.  
 
3.2 SPECIFIC AIMS 
 
Figure 2 presents the development of the specific research questions addressed in this thesis. 
All research questions were developed in collaboration with clinicians at the Obesity Center. 
 
 
 
 
 
 
Figure 2. Overview of the development of Studies I-IV. 
 
Clinical perceptions of young adults (16-25 years) in behavioral treatment for severe obesity before and after bariatric surgery: 
 
Low levels of 
cardiometabolic 
comorbidities, but high 
levels of mental health 
problems. 
High prevalence of 
mental distress 
compared to non-
treatment-seeking 
young adults with 
different BMI levels.   
 
Poor results in weight 
reduction treatment 
compared to older 
adults (≥26 years), 
concerning weight loss 
and drop-out. 
    Characterization (Studies I-II) Aspects of treatment (Studies III-IV) 
Concerns about mental 
health and health-related 
quality of life outcomes 
after bariatric surgery.   
Specific aims: 
 
1) To perform a comprehensive characterization of treatment-seeking young adults with severe obesity and to study variables 
associated with mental health in the same cohort (Study I). 
 
2) To compare the rates and levels of mental distress in treatment-seeking young adults with severe obesity versus the general 
population (Study II). 
 
3) To compare long-term results regarding weight loss, adverse events, loss-to-follow-up and health-related quality of life in 
young (18-25 years) versus older (≥26 years) adults after bariatric surgery (Studies III-IV). 
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3.3 RESEARCH QUESTIONS 
Five research questions were developed to examine the specific aims as presented above. 
These five research questions in turn framed the thesis into two main areas of interest, (1) 
characterization and (2) treatment of young adults with severe obesity. Both research areas 
involved aspects of mental health.  
1. What sociodemographic and life style factors characterize young adults (16-25 years) with 
severe obesity who seek behavioral weight reduction treatment, and what is the prevalence of 
obesity-related comorbidities, cardiometabolic risk factors, micronutritional deficiencies, 
mental health problems and issues in health-related quality of life (HRQL) in the same 
cohort? (Study I) 
2. What variables are associated with mental distress in young adults (16-25 years) with 
severe obesity who seek behavioral weight reduction treatment? (Study I) 
3. What is the prevalence of mental distress in young adults (18-25 years) with severe obesity 
who seek behavioral weight reduction treatment compared to population controls with 
different BMI levels? (Study II) 
 Studies I-II: Characterization  
 
4. What are the (5-year) outcomes of Roux-en-Y gastric bypass in young (18-25 years) vs 
older (≥26 years) adults concerning weight loss, adverse events and loss-to-follow-up? (Study 
III) 
5. What is the level of HRQL before and 5 years after Roux-en-Y gastric bypass in young (18-
25 years) vs older (≥26 years) adults? (Study IV) 
 Study III-IV: Aspects of treatment 
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4 METHODS 
Table 1 presents an overview of study I-IV including specific aims, study design, study 
setting and main measures.  
 
4.1 STUDY SETTING 
Studies I-II were based on clinical data collection from the Obesity Center at the Karolinska 
University Hospital (Studies I-II) and population control data from the Stockholm Public 
Health Cohort (Study II). Studies III-IV were based on registry data from the Scandinavian 
Obesity Surgery Registry (SOReg).  
The Karolinska University Hospital Obesity Center (Studies I-II) 
The Obesity Center at the Karolinska University Hospital provides individualized behavioral 
weight reduction treatment including individual coaching sessions based on cognitive 
behavioral therapy and acceptance cognitive therapy, group sessions, motivational 
interviewing, and physical activity training. The professional team includes obesity-trained 
physicians, nurses, physiotherapists, occupational therapists and psychotherapists. Patients 
≥18 years who fulfill the criteria for bariatric surgery may be evaluated by a physician for 
referral to bariatric surgery centers.  
Since 2007, young adults (16-25 years) are offered specialized obesity care according to the 
“youth friendly service” concept 242, including a greater focus on patient autonomy and to a 
lesser extent the family involvement that pediatric treatment is generally based on. Compared 
to older adults (≥26 years), treatment of young adults is focused on more concrete problem-
solving, and the young adults are contacted for several years after drop-out in order to 
facilitate re-connection with the Obesity Center and thus continuation of treatment. In 2012, a 
compulsory pre-bariatric surgery care program for 18-to-25-year-olds was incorporated into 
the Stockholm Regional Obesity Treatment Guidelines, which were to be delivered by the 
Obesity Center. Since 2015, the Obesity Center also provides post-bariatric surgery care for 
young adults.  
Referral requirements to the young adult section are: age 16-25 years and BMI ≥35 kg/m2 or 
BMI ≥30 kg/m2 together with obesity-related comorbidities except for current eating 
disorders according to DSM-IV criteria 243 (these patients are referred directly to eating 
disorder specialist clinics). The young adult patients may be referred to the Obesity Center 
from primary care physicians, hospital-based physicians (mainly pediatricians) and school 
nurses throughout Stockholm City County.  
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Table 1. Overview of specific aims, design, study setting and main measures for Studies I-IV. 
Study: Specific aim: Design and study 
setting: 
Main measures: 
Matching variables: Main outcomes: Covariates: 
 
 
 
I 
(1) To perform a comprehensive 
characterization of sociodemographic 
factors, lifestyle factors, obesity-related 
comorbidities, cardiometabolic risk 
factors, micronutritional deficiencies, 
mental health issues and HRQL in 
treatment-seeking young adults with 
obesity and (2) to study variables 
associated with mental health in the same 
cohort. 
Cross-sectional 
cohort study. 
- BMI, occupation, nationality, 
socioeconomic status, sexuality, 
VO2max, smoking, alcohol drinking, 
sleep impairment, obesity-related 
comorbidities and 
medications/treatments, cardiometabolic 
risk factors and micronutritional status, 
insomnia, suicidal behavior, depressive 
and anxiety symptomatology, ADHD 
symptomatology, self-esteem, SF-36, 
Obesity-related Problems scale. 
BMI, age, gender, 
socioeconomic status, 
hazardous alcohol drinking, 
insomnia, insulin resistance, 
social support.  
Obesity Center. 
 
 
II 
To compare the rates and levels of mental 
distress in treatment-seeking young adults 
with obesity vs the general population 
with different BMI levels.  
Cross-sectional, 
matched, cohort 
study. 
Age, gender, 
socioeconomic status. 
Mental distress, depression, suicidal 
behavior, physical/psychosomatic 
symptoms, quality of life. 
Age, gender, socioeconomic 
status, smoking, hazardous 
alcohol drinking, physical 
disease, sexual orientation, 
social support. 
Obesity Center 
and Stockholm 
Public Health 
Cohort. 
 
 
III 
To compare weight loss, adverse events 
and loss-to-follow-up in young (18-25 
years) vs older (≥26 years) adults up to 5 
years after Roux-en-Y gastric bypass. 
Prospective 
registry-based 
observational 
matched cohort 
study. 
BMI, gender, year of 
surgery. 
Weight loss, adverse events, loss-to-
follow-up. 
BMI, gender, year of surgery, 
obesity-related comorbidities, 
surgical access, duration of 
surgery, surgical volume, 
concurrent surgery.  
SOReg. 
 
IV 
To compare HRQL between and within 
young (18-25 years) vs older (≥26 years) 
adults 5 years after Roux-en-Y gastric 
bypass.  
 
Prospective 
registry-based 
observational 
matched cohort 
study. 
BMI, gender, year of 
surgery. 
SF-36, Obesity-related Problems scale.  SF-36, Obesity-related 
Problems scale at baseline, 
obesity-related comorbidities, 
weight loss at 5 years, adverse 
events, surgical access. 
SOReg. 
Abbreviations: HRQL, health-related quality of life; BMI, body mass index; ADHD, attention deficit hyperactivity disorder; SF-36, Short Form-36; SOReg, Scandinavian Obesity 
Surgery Registry
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The Stockholm Public Health Cohort (Study II) 
Since 2002, the Stockholm Public Health Cohort prospectively collects self-reported data 
every fourth year on a random sample of Stockholm citizens aged 18 years and above. Data 
are collected by postal or web-based questionnaires, and include anthropometry, 
demography, lifestyle habits, physical and psychosocial work environment, and mental 
health. Data from 2010 were included in the present thesis, and the response rate for the total 
cohort that year was 57% with generally lower rates in participants <45 years of age. Drop-
out was more frequent in men than women, in younger than older responders, in non-native 
than native Swedes and in responders of low than high socioeconomic status. A detailed 
description of the cohort was published by Svensson et al 244. 
The Scandinavian Obesity Surgery Registry (Studies III-IV) 
The Scandinavian Obesity Surgery Registry (SOReg, http://www.ucr.uu.se/soreg/) is a 
quality and research registry, financed by the Swedish Association of Local Authorities and 
the National Board of Health and Welfare, and has been running in its present form since 
2007. SOReg covers all bariatric surgery centers in Sweden, irrespective of financing source 
245. The registry covers surgery-related technicalities, procedures, anthropometry, adverse 
events and HRQL. Data are collected by a nurse or surgeon approximately 1 month before 
surgery, on the day of surgery, and at 6 weeks/1 year/2 years/5 years/10 years post-
operatively as part of standard care either by a physical visit, telephone or email. Mortality 
data in SOReg are cross-matched with the Swedish Population Register. A detailed 
description of the registry was published by Hedenbro et al 246 and annual follow-ups are 
published with public access at the SOReg homepage (http://www.ucr.uu.se/soreg/).  
For 2007-2010, the coverage was 80-90% for all bariatric procedures in Sweden. From 2011 
and onwards, the coverage was 97% 107. According to regular audits with random 
comparisons of the patient medical records and the Swedish Population Register, 96.7-98.6% 
of SOReg data was correctly registered 246 247. Routines for follow-up may differ between 
operating centers due to differences in economical compensation schemes throughout 
Sweden, albeit all participating centers are pledged to register for at least 1 year.  
 
4.2 RECRUITMENT 
Study I 
Only enrollees to the Obesity Center were included in Study I. Patients with eating disorders, 
language barriers or intellectual disabilities were excluded from participation. Data and 
consent were collected at the second visit to the Obesity Center. See Figure 3 for an 
overview of the data collection process. Eighty-seven percent (n=236) of those accepted for 
clinic enrollment met the study inclusion criteria, and 70% (n=165) of eligible patients 
participated.  
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                 n=270                           n=236                                n=165 
Figure 3. Overview of data collection and numbers of participating patients in Study I.  
Abbreviations: BMI, body mass index; n, numbers. 
 
Study II 
Data on treatment-seekers aged 18-25 years who enrolled in Study I were included in Study 
II together with two datasets of responders to the Stockholm Public Health Cohort from 2010. 
The first dataset consisted of responders with any BMI level that were individually matched 
1:3 with treatment-seekers for age, gender and socioeconomic status. The second dataset 
consisted of all responders aged 18-25 years with BMI ≥30 kg/m2 (matching here would have 
resulted in insufficient statistical power). Responders with obesity were categorized as having 
obesity class I or severe obesity. Figure 4 presents an overview of the two cohorts. Seventy-
nine percent (n=212) of 270 patients who were accepted for enrollment to the Obesity Center 
during the study period met the inclusion criteria, whereof 57% (n=121) participated in the 
study. A selection of questions from the Stockholm Public Health Cohort questionnaire was 
included in the questionnaire that was handed out to the treatment-seekers in order to obtain 
the same items for treatment-seekers and controls.   
 
 
 
    Figure 4. Overview of cohort I and II in study II.  
    Abbreviations: n, numbers; BMI, body mass index. 
 
Data checking and 
entry in file by 
researcher 
 
 
 
 
 
Referral criteria: 
 
Age: 16-25 years; 
BMI ≥35 kg/m2 or 
≥30kg/m2 with an 
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Responders to the 
Stockholm Public Health 
Cohort (18-25 years) with 
BMI ≥35 kg/m2 (n=41). 
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Studies III - IV 
Studies III-IV included only patients who were registered in SOReg and who had undergone 
RYGB. Young adults (18-25 years, n=3,531) who were included between May 2, 2007 (the 
initiation of SOReg) and December 30, 2013 were frequency matched to older adults (≥26 
years, n=17,137) for BMI, gender and year of surgery. Patients were followed up 6 weeks, 1, 
2 and 5 years after RYGB. The last day of data entry was September 15, 2015, which is why 
all included patients were not eligible for 2- and 5-year follow-up. Data were extracted on 
Feb 8, 2016. See flowchart in Figure 5 for details.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Study III flow chart. Numbers (n) of young (18-25 years) and older (≥26 years) adults, matched for 
body mass index at baseline, gender and year of surgery, at baseline, and 6 weeks, 1, 2 and 5 years after Roux-
en-Y gastric bypass.  
 
* Not eligible for 2- and 5-year follow-up.  
 
5 years 
n=2,210 
 
Missed appointment (n=955) 
No attempt to contact patient (n=311) 
Surgery after 09/15/2010* (n=12,345) 
Deceased (n=36) 
Missing data (n=1,280) 
 
6 weeks 
n=16,631 
 
1 year 
n=15,298 
 
Missed appointment (n=381) 
No attempt to contact patient (n=94) 
Deceased (n=4) 
Missing data (n=27) 
 
Missed appointment (n=1,088) 
No attempt to contact patient (n=414) 
Deceased (n=16) 
Missing data (n=321) 
 
2 years 
n=9,959 
 
Missed appointment (n=1,965) 
No attempt to contact patient (n=1,547) 
Surgery after 09/15/2013 * (n=1,203) 
Deceased (n=30) 
Missing data (n=2,433) 
 
6 weeks 
n=3,328 
 
1 year 
n=2,900 
 
Missed appointment (n=430) 
No attempt to contact patient (n=149) 
Deceased (n=2) 
Missing data (n=50) 
 
2 years 
n=1,831 
 
Missed appointment (n=632) 
No attempt to contact patient (n=381) 
Surgery after 09/15/2013* (n=242) 
Deceased (n=4) 
Missing data (n=441) 
 
Missed appointment (n=257) 
No attempt to contact patient (n=95) 
Surgery after 09/15/2010 * (n=2,533) 
Deceased (n=2) 
Missing data (n=275) 
 
5 years 
n=369 
 
Scandinavian Obesity Surgery Registry, 
matched cohort. Study III. 
Data collection: May 2, 2007 – September 
Young adults (18-25 years) Older adults (≥26 years) 
Baseline 
n=3,531 
 
Baseline 
n=17,137 
 
Missed appointment (n=175) 
No attempt to contact patient (n=23) 
Missing data (n=5) 
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The cohort in Study III constituted the population base also for Study IV. However, since 
data on the main outcome for Study IV (HRQL) were missing for a number of entries, the 
original cohort was reduced to n=2,542 young (18-25 years) and n=12,425 older (≥26 years) 
adults at baseline. In Study IV, the patients were followed up at 1, 2 and 5 years after RYGB. 
See flowchart in Figure 6 for details.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Study IV flow chart. Numbers (n) of young (18-25 years) and older (≥26 years) adults, matched for 
body mass index at baseline, gender and year of surgery, at baseline, and 1, 2 and 5 years after Roux-en-Y 
gastric bypass.  
 
* Not eligible for 2- and 5-year follow-up.  
 
4.3 MAIN MEASURES 
The included measures are used interchangeably as either matching variables, main outcomes 
and/or covariates throughout Studies I-IV depending on study design and aim. Table 1 
presents the measures included in Studies I-IV including the specific purpose (matching 
2 years 
n=777 
 
5 years 
n=138 
 
Missed appointment (n=194) 
No attempt to contact patient (n=59) 
Surgery after 09/15/2010 * (n=1,897) 
Deceased (n=4) 
Missing data (n=250) 
 
1 year 
n=8,487 
 
2 years 
n=4,816 
 
Missed appointment (n=757) 
No attempt to contact patient (n=307) 
Deceased (n=11) 
Missing data (n=2,863) 
 
5 years 
n=1,021 
 
Missed appointment (n=1422) 
No attempt to contact patient 
(n=1,168) 
Surgery after 09/15/2013 * (n=899) 
Deceased (n=25) 
Missing data (n=157) 
 
Missed appointment (n=739) 
No attempt to contact patient (n=207) 
Surgery after 09/15/2010 * (n=9,216) 
Deceased (n=70) 
Missing data (n=1,068) 
 
Older adults (18-25 years) 
n=17,137 
Baseline 
n=12,425 
 
No data on health-related quality of 
life at baseline (n=4,712) 
 
Scandinavian Obesity Surgery Registry,  
matched cohort. Study IV. 
Young adults (18-25 years) 
n=3,531 
Baseline 
n=2,542 
 
1 year 
n=1,440 
 
Missed appointment (n=312) 
No attempt to contact patient (n=119) 
Missing data (n=671) 
 
Missed appointment (n=464) 
No attempt to contact patient (n=246) 
Surgery after 09/15/2013 * (n=194) 
Deceased (n=2) 
Missing data (n=196) 
 
No data on health-related quality of 
life at baseline (n=989) 
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variable/main outcome/covariate) of each measure per study. A brief description of each 
included main measure in Studies I-IV is presented below.   
Anthropometric variables (Studies I-IV) 
For Study I and for treatment-seekers in Study II, weight, height and waist circumference 
were measured in light clothing by a trained nurse using a digital calibrated scale and a wall-
mounted stadiometer. The population controls in Study II self-reported weight and height. 
For Studies III-IV, weight, height and waist circumference were measured either by 
healthcare staff at physical appointments, or self-measured and reported by the patient via 
email or telephone. For Studies III-IV, weight loss was reported as percentage weight loss, 
loss of BMI units and excessive weight loss (EWL, proportion of preoperative BMI ≥25 
kg/m2 lost).  
Socioeconomic status (Studies I-II) 
Socioeconomic status was reported in Study I and was included as a matching variable in 
Study II. In both studies, socioeconomic status was measured using a question on economic 
strain: “Did you experience any difficulties coping with private expenditures during the last 
year?”. 
Lifestyle (Studies I-IV) 
In Study I, cardiorespiratory fitness in terms of VO2/kg * min was assessed using Åstrand’s 
submaximal bicycle ergometer test and categorized into very poor, poor, average and fair, 
taking gender and age into account 248. 
Smoking was included as a self-reported measure in Studies I-IV. Alcohol intake was also 
self-reported in Studies I-II, and values were summarized as units alcohol/week (1 unit=12 g 
of 100% alcohol 249) or hazardous drinking (weekly consumption of 14 units for men and 9 
units for women, or consumption of 5 units for men or 4 units for women on the same 
occasion 249). 
Sleep impairment during the past 3 months was measured in Study I by the self-reported 18-
item Karolinska Sleep Questionnaire (KSQ) which covers insomnia, disturbed sleep, 
nightmares, snoring and daytime sleepiness on a 6-item Likert scale 250.  
Obesity-related comorbidities, cardiometabolic risk factors and micronutritional status 
(Studies I-IV) 
For Studies I-II, present and life-time incidence of obesity-related comorbidities and 
corresponding medications and treatments were collected through items in the 
questionnaire and by the physician’s examination including checking the patient records. In 
Studies III-IV, obesity-related comorbidities were restricted to current pharmacological 
treatment for diabetes type 2, hypertension, dyslipidemia, depression, and/or usage of 
continuous positive airway pressure treatment for sleep apnea. For Study I, cardiometabolic 
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risk factors and micronutritional status were assessed using blood samples including fasting 
p-glucose, b-HbA1c, total cholesterol, p-LDL cholesterol, p-HDL cholesterol, p-
triglycerides, p-alt, s-ferritin, total iron binding capacity, b-HB, s-25-OH-vitamin-D 25, b-
folate, s-cobalamin and s-zinc. Age-adjusted cut-offs for metabolic risk factors were 
applied. Insulin resistance was calculated using the HOMA index 251. 
Mental health and quality of life (Studies I-IV) 
Mental health and quality of life were evaluated using validated questionnaires including 
the Hospital Anxiety and Depression Scale (HADS) 252, the Rosenberg Self-Esteem Scale 
(RSES) 253, and the Adult ADHD Self-Report Scale (ASRS) 254 in Study I; the General 
Health Questionnaire-12 (GHQ-12) 255 and separate questions on physical/psychosomatic 
symptoms in Study II 256; EuroQol-5D (EQ-5D) 257 and separate questions on previous 
suicidal behavior in Studies I-II 256; and the Obesity-related Problems scale (OP) 258 and 
Short Form Health Survey-36 (SF-36) 259 in Studies I and IV: 
The 14-item Likert HADS scale is used for detection of both anxiety and depressive 
symptomatology in outpatient adolescents and adults. The items are scored 0-3 points each 
and summarized into one anxiety measure and one depressive measure; thereafter they are 
categorized according to: no impairment (≤7 points), subclinical impairment (8-10), and 
clinical impairment (≥11). Patients above the subclinical cut-off should be considered for 
further clinical evaluation 260. 
The 10-item RSES is scored using a 4-point Likert scale to detect low self-esteem. The 
most widely used cut-off for low self-esteem is <15 points 253.  
ASRS assesses symptoms of concentration and hyperactivity associated with ADHD in 
patients ≥16 years old. The responses of the 6-item questionnaire are summarized into a 
score of 0-6 points: a score of ≥4 points indicates ADHD symptomatology 254.  
The 12-item GHQ is used to detect psychiatric symptomatology in surveys or clinical 
settings 261. GHQ-12 may be scored using either the Likert (0-3 points/item which are 
summarized into a continuous score of 0-36 points) or the GHQ (one point / positive reply 
is summed up to a maximum score of 12 points) scoring methods. While there is no cut-off 
for mental distress using the Likert scale, a cut-off of  ≥3 points is used with the GHQ scale 
255.  
Questions on physical/psychosomatic symptoms were retrieved from the Stockholm Public 
Health Cohort questionnaire and included “Are you bothered by any of the following 
symptoms? Headache/hyperacusis/urinary incontinence/acid reflux/fatigue/tinnitus”, with 
the possible responses of “no”, “yes, mild” and yes, severe” 256.  
EQ-5D measures five dimensions of quality of life: mobility, hygiene, daily activities, pain 
and anxiety. There are three possible levels (no/some/extreme problems) and together the 
dimensions are converted into an index score, which is summarized differently across 
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countries. The British time-trade-off method was used in Studies I-II. EQ-5D is mostly used 
in community settings. A low score is associated with impairment of quality of life 257.  
Suicidal behavior was measured using two separate questions: “Have you ever had suicidal 
thoughts” and “Have you ever tried to commit suicide?”. Possible responses were “yes, ≥1 
year ago”, “yes, <1 year ago”, “yes, last week” or “no, never 256. The questions were 
repetitively used in the Stockholm Public Health Cohort and were initially developed by the 
National Centre for Suicide Research and Prevention of Mental Ill-Health and were also 
repetitively included in the Swedish national public health questionnaire. The responses 
were found to correlate well with self-rated health, mental distress and anxiety, among 
others 262.  
OP includes questions on obesity-related limitations in eight activities of daily living such 
as buying clothes and swimming, and was frequently used in Swedish obese samples, 
including bariatric cohorts such as the SOS study 263. A summary score of 0-100 is 
calculated, with lower scores indicating better psychosocial functioning and categorized as: 
mild (<40 points), moderate (40-59 points) or severe (≥60 points) psychosocial impairment 
258.  
SF-36 measures HRQL using 36 questions on functional physical and mental health in the 
last 4 weeks. The responses are summarized into eight domains each ranging from 0 to 100, 
with 100 indicating optimal health. A summary component score of mental and physical 
health is calculated, with a score of 50 indicating the population mean 259.  
Methodological considerations on the construct of questionnaires 
The construct of questionnaires necessitates some deliberation to reduce the risk of drawing 
false conclusions. I will here therefore discuss certain questionnaire properties that were 
considered when selecting questionnaires for Studies I-IV: the level of reliability and validity 
and the risk of response bias. 
Measurements of reliability and validity are central when validating a new questionnaire. 
High reliability means that the results are consistent between ≥2 measurements, and high 
validity means that the questionnaire measures what it is intended to measure. Reliability and 
validity may preferably be evaluated for different populations and languages.  
Internal consistency and test-retest variability are two ways of evaluating reliability. Internal 
consistency reflects to what extent the items are correlated to each other. High internal 
consistency means that responders replied in a similar way to items of similar meanings. 
Thus, internal consistency is low if a respondent replies yes to both “I love food” and “I hate 
food”. Internal consistency is measured by Cronbach’s alpha and ranges between negative 
infinity and one. A score ≥0.9 equals excellent internal consistency 264. Test-retest variability 
refers to what extent a responder replies in a similar way if asked to repeat his/her responses. 
Test-retest variability is assessed by Pearson’s product-moment correlation coefficient. The 
larger the coefficient, the more stable the responses and thus better test-retest variability.   
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Validity refers to the content and construct validity. A content-valid questionnaire indicates 
that the included items are representative for what the questionnaire is designed for and 
intended to assess. When constructing a new questionnaire, the content validity may for 
example be evaluated by an expert in the field. A questionnaire of high construct validity 
means that inferences may be drawn from the responses to actual behavior or other pre-
existing measurements. For example, a score that indicates high levels of leg pain, should 
correlate to difficulties walking. Construct validity is measured by correlation coefficients 
with ≥0.5 points indicating high correlation between constructs 265.  
Concerning validation of the questionnaires in the present thesis, HADS, RSES, GHQ-12 and 
SF-36 were validated in ≥16-year-olds 261 266 267-269. ASRS was constructed for ≥16-year-olds, 
although validated in ≥18-year-olds only 270. OP was used in 16-to-17-year-olds 271, but 
validated for ≥18-year-olds. KSQ and EQ5D were validated in ≥18-year-olds. The separate 
questions were tested within the Stockholm Public Health Cohort (≥18-year-olds), but not 
properly validated. HADS, RSES, ASRS, OP and EQ5D had been extensively used in 
clinical care at the Obesity Center before the initiation of Studies III-IV, and we thus had 
real-life experience from using them in the population that we were to study.  
Response bias may arise secondary to miscommunication between the responders and the 
researchers, misunderstanding of the questions, problems with recalling necessary 
information, lack of motivation to undergo the survey, contextual cuing (e.g. that the 
respondent tends to think more about his/her health if surveyed in a hospital setting than in 
everyday life), socially desired responding and language barriers, among others. Such 
response biases may cause repeated tendencies to respond in specific patterns, which may 
distort the data. Response bias must therefore be considered when deciding how and in what 
setting responders will answer the questionnaire. In clinical obesity research, impression 
management secondary to desire to undergo bariatric surgery is of particular concern.  
Adverse events (Study III) 
An adverse event was defined as a postoperative course that was aberrant from the normally 
expected course. Adverse events were registered in SOReg by a surgeon if a complication 
occurred, and otherwise by a nurse (i.e. in the case of negative responses). An adverse event 
that occurred between surgery and 6 weeks was registered at 6 weeks, and an event that 
occurred between 6 weeks and 1 year was assessed at 1 year etc.  
Adverse events included post-surgery complications such as leak, bleeding, abscess, wound 
complications, port-related complications, cardiovascular complications, venous 
thromboembolism and urinary tract infection. Long-term complications included ileus, 
anastomotic stricture, stomal ulcer, perforation, hernia, anemia/malnutrition requiring 
intervention or other non-specified surgery-related adverse events such as biliary stones. The 
Clavien-Dindo classification of the severity of adverse events was added on May 1, 2010. 
Clavien-Dindo 2-3a, i.e. adverse events requiring medication or intervention under local 
anesthesia, were classified as significant, and Clavien-Dindo 3b-5 (including mortality due to 
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a complication), i.e. adverse events requiring an intervention under general anesthesia, were 
defined as serious.  
Loss-to-follow-up (Study III) 
Loss-to-follow-up was categorized as “Missed appointment”, meaning that the patient was 
invited to a follow-up visit (physical visit/telephone/email) but did not turn up; “No attempt 
to contact patient”, meaning that the caregiver had not invited the patient to follow-up; and 
“Total loss-to-follow-up”, meaning those mentioned above plus missing data and deceased.  
Uncategorized variables (Studies I-IV) 
Variables not classified into any of the above categories included employment status (Studies 
I-II); sexual orientation and social support (Studies I-II), all measured by items from the 
Stockholm Public Health Cohort; nationality (Study I), measured by questions on country of 
birth and parents’ country of birth; surgical access (Studies III-IV), categorized as 
laparoscopic, open or converted; duration of surgery in minutes (Study III); and high-volume 
center (Studies III-IV), defined as a surgery center that in a certain year performed more than 
the median number of RYGB surgeries for that specific year. The above mentioned non-
surgical variables were not validated; however, they had been frequently used and found 
applicable in previous Stockholm Public Health Cohorts 256.  
 
4.4 STATISTICAL ANALYSES 
Background to statistical tests included in Studies I-IV 
The statistical analyses used in Studies I-IV are accounted for in Table 2; below, I briefly 
discuss the background for using each test in the respective study.  
 
Table 2. Statistical analyses used in Studies I-IV.  
 
Statistical analysis Study I Study II Study III Study IV 
Chi2-test  x x x 
Independent samples t-test x x x x 
Mann-Whitney U test  x x x 
Paired samples t-test x    
Paired samples sign test    x 
Multiple regression x x  x 
Logistic regression   x  
Poisson regression  x x  
Linear mixed effects models   x  
 
Chi2-test (used in Studies II-IV) was used to test whether there was an association between 
two independent categorical variables, and the independent samples t-test (Studies I-IV) was 
used when testing whether there was a difference in mean between two independent groups 
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on a normally distributed continuous variable. The difference in distribution between two 
non-normally distributed independent samples was analyzed using the Mann-Whitney U test 
(Studies II-IV). The paired samples t-test (Study I) was used to test whether there was a 
difference between two measurement points in a normally distributed variable in the same 
sample. In a non-normally distributed sample with different distributions between the two 
dependent samples, the paired samples sign test (Study IV) was applied.  
In multiple regression (Studies I-II, IV) a dependent continuous variable (the outcome) is 
studied in relation to independent continuous or categorical variable(s) which are linearly 
related to the dependent variable. The multiple regression analysis will estimate a linear 
equation in terms of: Y = β0 + β1X1 + β2X2… + βpXp  + ɛi, where Y is the dependent 
variable, β0 is the constant, β is the regression coefficient, X is the independent variable(s) 
and ɛi is the error term.  
Logistic regression (Study III) was used to calculate the probability of an independent 
variable falling into one of two categorical variables. Logistic regression was used to study 
ORs between groups. Odds is calculated by dividing the probability of X to occur, with the 
probability of X not to occur written as P/(1-P). OR is calculated by dividing the odds of an 
exposed group with the odds of an unexposed group written as (a/b)/(c/d). OR approximates 
and may be interpreted as relative risk in samples with infrequent prevalence of the outcome 
(approximately <10%), but overestimates the relative risk in samples with large 
(approximately ≥10%) prevalence of the outcome 272. 
Poisson regression (Studies II-III) is generally used to predict count data (the dependent 
variable) in relation to independent variables, and to determine the percentage difference in 
counts of the dependent variable between categorical independent variables, or in relation to 
one unit’s step up/down of continuous variables. Poisson regression thus calculates the risk 
ratio (relative risk), i.e. the risk of X occurring in an exposed group vs X occurring in another 
group, written as a/(a+b) / c/(c+d). However, Poisson regression may also be used to analyze 
dichotomous data and may as such be an alternative to logistic regression in samples with 
large frequencies of the outcome 272 273.  
Linear mixed effects models (Study III) handle correlated data, such as repetitive 
measurements, and data that are unbalanced (i.e. included subjects do not display the same 
numbers of observations, and the observations are made at different times). Linear mixed 
effects models are therefore an advantage in datasets with missing data (see below). 
Moreover, the mixed effects approach, taking random and fixed effects into account, may 
describe the unique “behavior” of each variable (individual) that is included in the analysis. 
Accordingly, all data are not to be fitted into one single regression line (which is seldom 
accurate when depicting real-life data), but instead one line per individual.  
All statistical tests were two-sided and calculated with 95% CI. A p-value <0.05 was 
considered statistically significant. All data were analyzed using SPSS version 22-23. 
  31 
The clinical relevance of the differences/changes in HRQL (Study IV) was measured by 
effect size, Cohen’s d (average scoregroup1 – average scoregroup2/pooled standard deviation) 274. 
Effect size was categorized into negligible (<0.2), weak (0.2-0.5), average (0.5-0.8) and large 
changes (>0.8).  
Missing data 
Missing data is common in real-life settings in medical research, and particularly so in 
longitudinal studies. Missing data increase the risk for biased results. Traditional statistical 
analyses of longitudinal data, such as repeated measures ANOVA, may lose power when 
handling unbalanced data, as subjects with missing data will be discarded from the analyses 
(listwise deletion/completers only analyses). One way to handle this is to impute data (Study 
III-IV) which allows subjects with incomplete data to be included in the analyses.  
There are a number of ways to impute data, such as “baseline carried forward” (Study III-
IV), where the baseline value of the variable for each subject is imputed for all missing data 
entries. In “last observation carried forward” (Study III-IV), the last entered data point 
before the missing value is imputed. In “multiple imputation” several different hypothetical 
complete datasets are created by predicting the missing values by means of predefined 
variables from the original dataset. Missing data in the original file are thereafter replaced by 
the new datasets. Eventually, the results of the analyses with imputed data are compared with 
the results of the original analyses with missing data 275. Since the new dataset is dependent 
on the complete cases, the results of multiple imputation are generally similar to results in 
completers-only analyses.   
Modern statistical methods in terms of mixed models (Study III, see above) use the full 
dataset, irrespective of whether data are missing or not. However, unbiased results are created 
only if data were missing at random, since mixed models will make use of the complete data 
when estimating means.    
In order to detect any crucial differences between missing and complete data, the baseline (or 
other) variables in data that were missing are generally compared with the baseline variables 
in data that were not missing (Studies III-IV) using appropriate tests as described above.  
Matching 
Matching is a statistical technique which is used to reduce bias when comparing independent 
groups 276. The aim of matching is to create a dataset with the same values in one or several 
confounders in all matching groups. Matching is generally achieved on an individual basis, 
i.e. that each individual in group A has the same value of the confounding variable(s) as a 
paired individual in group B (Study II). Alternatively, the proportion of the confounding 
variable is the same across groups A and B, so-called frequency matching (Studies III-IV).  
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5 ETHICAL CONSIDERATIONS 
Swedish healthcare policies should be built on the four basic principles of medical ethics: 
autonomy, beneficence, non-maleficence and justice. These principles are intended to guide 
clinicians through medical decision-making to provide what is regarded as beneficial health 
services for the whole population. In this chapter I consider the above-mentioned principles 
in the light of the present thesis.  
Autonomy, meaning that an informed, adult, person is able to decide for him/herself about 
his/her life as long as the decision does not conflict with other people. In a medical setting, 
autonomy means that a patient may refuse or accept treatments, and that his/her decision must 
be respected by the healthcare workers. Hence, the patient preferably needs reliable 
information on positive as well as negative effects of a specific treatment before he/she is 
able to decide whether he/she wants to undergo that specific treatment. Results from children 
and adults have generally been applied to young adults, without examining what needs may 
be specific to the young adult population. A central theme of this thesis is to shed light on 
young adults, i.e. to acknowledge young adults as independent individuals and not as 
random “above 18 years old people”. Here, I argue that fulfilled autonomy cannot be 
achieved unless young adults are addressed as an independent age group. Without 
considering whether a treatment option differs in outcome between certain age periods, and 
the lack of research on whether this is the case, the patient is left non-informed on age-
specific outcomes. Increased autonomy is becoming more important as a means of 
improving Swedish healthcare services, since reports show that Swedish patients feel less 
involved in decision-making compared to other OECD countries 277. 
When discussing autonomy, one may argue against the use of the term “young adult” since 
this term may imply that the young person does not “stand alone” from the adult age group. 
“Young” is here related to “adult”, and thereby linguistically dependent on another age group. 
As discussed in the introduction, the terminology for people in between adolescence and 
mature adulthood varies and, in hindsight, we could have considered the terminology in a 
broader perspective in order to fully acknowledge the uniqueness of our patient group.  
Beneficence - doing what is best for the patient – is clearly not achieved unless treatment 
options are thoroughly evaluated. Obviously, research on treatment effects, for example 
Studies III-IV, contribute such data. However, what is considered as “medical good 
quality” according to medical professionals, may not be as important from a patient’s 
perspective. For example, weight loss has historically been the overall aim in general 
obesity medicine, while patients with obesity may be suffering more from obesity stigma, 
than body fat per se. With such a perspective, “doing what is best for the patient” might be 
to focus on self-acceptance instead of eating less calorie-dense food. Therefore, in 
hindsight, inclusion of patients’ narratives in the present thesis would have enhanced the 
picture of severe obesity in young adulthood.  
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The concept of beneficence is closely linked to non-maleficence – i.e. do no harm (“primum 
non nocere”). Studies on adverse events are therefore as important as studies on positive 
treatment effects (Study III). However, one may argue that the ethical concept of “do no 
harm” only includes intentional overt actions or adverse events which are necessary to 
achieve the positive effects. Such acceptance of harmful actions is theorized as “the double 
effect doctrine” (Thomas Aquinas, Summa Theologica II-II, Qu. 64, Art.7). In this 
perspective, unknown and unintentional adverse events of bariatric surgery are accepted if the 
intention with surgery is “good” and if the “good” outweighs the “bad”. Consequently, to 
know whether good outweighs bad, one must study what might be “bad” in addition to what 
is supposed to be “good”, such as weight loss and resolution of comorbidities. 
Justice means that health care should allocate the resources in a fair manner because 
resources are scarce. In Swedish healthcare, priority should be offered according to medical 
needs, meaning that patients with serious needs should be served before those with less 
serious needs. Importantly, having a “need” of something, means that this “something” has a 
predominantly positive effect on the need so that the need is consequently reduced 278. Hence, 
a fair decision on who should be served first cannot be made unless we know the treatment 
outcome, which consequently makes evaluations of treatments a central issue. 
Importantly, to know whether treatment effects actually do good or harm, results must be 
reliable, meaning that the methodology must be accurate and thoroughly discussed. 
Consideration of “limitations and strengths” is obviously central in all medical research.  
All studies in the present thesis were approved by the Stockholm Ethical Review Board: 
2012/1154-31/4 (Studies I-II) and 2012/1217-31/5 (Studies III-IV) 
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6 RESULTS 
6.1 RESULTS OF CHARACTERIZATION / RESEARCH QUESTIONS 1-3 
(STUDIES I-II)  
A total of n=165 young adult (16-25 years) treatment-seekers to the Obesity Center were 
included in Study I. Mean age was 19.7 years (SD: 2.7), 80% (n=132) were women, mean 
BMI was 39.2 kg/m2 (SD: 5.2), and 17% (n=28) were categorized as having obesity class I, 
41% (n=68) as obesity class II and 41% (n=67) as obesity class III and above.  
Sociodemographic and lifestyle factors, obesity-related comorbidities and risk factors, 
micronutritional deficiencies, mental health and HRQL of the treatment-seeking young adults 
are presented in Table 3-4. 
A multivariate regression analysis of anxiety and depressive symptomatology as measured by 
HADS demonstrated independent associations between anxiety symptomatology and pain 
(B=2.4) and low self-esteem (B=0.25; R2=0.33, p <0.001); and between depressive 
symptoms and cardiorespiratory fitness (B=0.18), poor psychosocial functioning (B=0.031) 
and low self-esteem (B=0.23; R2=0.38, p <0.001), when adjusted for age, gender, economic 
strain, hazardous alcohol drinking, insomnia, insulin resistance and social support. 
In Study II, a total of n=121 young adult (18-25 years) treatment-seekers with obesity were 
included. Mean age was 20.8 years (SD: 2.3), 81% (n=98) were women, and mean BMI was 
39.8 kg/m2 (SD: 5.3). An individually matched population cohort included n=363 young 
adults, with a mean age of 20.8 years (SD: 2.3), 81% (n=294) were women and mean BMI 
was 22.4 kg/m2 (SD: 4.0), all, p <0.05 for difference in matching variables between patients 
and controls. Five percent (n=18) of the population controls were classified as obese. While 
the two groups differed on percentage of tobacco smokers (25% in treatment-seekers, 16% in 
population controls), heterosexual orientation (83% vs 91%) and presence of social support 
(88% vs 94%), there was no statistical difference between groups in any of the other baseline 
characteristics (nationality, single household, occupation, hazardous alcohol drinking).    
The frequencies of mental distress in treatment-seekers vs population controls for any BMI 
level are presented in Table 5.  
In the second part of Study II we included n=146 unmatched young adult (18-25 years) 
population controls from the Stockholm Public Health Cohort with BMI ≥30 kg/m2 for 
comparison with the same treatment-seekers as in the first part (n=121). A total of n=105 
controls had obesity class I (BMI 30.0-34.9 kg/m2) with a mean BMI of 32.1 kg/m2 (SD: 
1.3), a mean age of 21.4 years (SD: 2.2), and 50% (n=52) of them were women. A total of 
n=41 controls had severe obesity with a mean BMI of 39.7 kg/m2 (SD: 5.3) a mean age of 
21.8 years (SD: 2.3) and 78% (n=32) of them were women.  
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Table 3. Sociodemographic and life style factors, obesity-related comorbidities and risk factors, and 
micronutritional deficiencies in n=165 young adult (16-25 years) treatment-seekers with severe obesity.  
Variable Treatment-seekers 
Sociodemographic factors, % (n)  
Occupation  
 Students 64 (106) 
 Employed 20 (33) 
 Unemployed 10 (17) 
 On sickness benefit ≥30 consecutive days 3 (5) 
Economic strain last year 19 (31) 
Born in Sweden 87 (143) 
Second-generation immigrant 19 (31) 
Lifestyle factors, % (n)  
Poor or very poor cardiorespiratory fitness (n=90) 92 (90) 
Daily tobacco smoker 22 (36) 
Hazardous alcohol drinker 17 (27) 
Sleep impairment (insomnia) 54 (88) 
Obesity-related comorbidities, % (n)  
Diabetes mellitus type 2 3 (5) 
Hypercholesterolemia 3 (5) 
Hypertension 2 (4) 
Polycystic ovary syndrome (women only) 10 (13) 
Non-alcoholic fatty liver disease 1 (2) 
Obstructive sleep apnea 0 (0) 
≥1 cardiometabolic obesity-related disease (any of those above) 16 (26) 
Asthma 21 (35) 
Hypothyroidism 7 (11) 
Cardiometabolic risk factors  
Fasting p-glucose, mmol/l; mean (SD) 5.4 (1.5) 
HbA1c, mmol/mol; mean (SD) 35.1 (7.1) 
Impaired fasting plasma-glucose (6.1–6.9 mmol/l) a; n (%)  3 (5) 
Increased p-glucose (≥7 mmol/l) c; % (n) 2 (3) 
Insulin, mlU/l; mean (SD) 26.6 (20.9) 
Insulin resistant according to the HOMA index 82 (129) 
Total cholesterol, mmol/l; mean (SD) 4.5 (0.9) 
LDL cholesterol, mmol/l; mean (SD) 2.8 (0.7) 
HDL cholesterol, mmol/l; mean (SD) 1.1 (0.2) 
Fasting triglycerides, mmol/l; mean (SD) 1.3 (0.6) 
≥1 plasma lipid abnormality b, % (n)  62 (98) 
ALT, μkat/L; mean (SD) 0.5 (0.5) 
Elevated ALT c, n (%)  22 (35) 
Micronutritional deficiencies, % (n)  
Depleted iron stores (serum-ferritin <12 μg/L or total iron binding capacity > 
400 μg/dL) 
17 (27) 
Iron-deficiency anemia (depleted stores or early functional iron deficiency and 
Hb <120 g/L (men) or <130 g/L (women) 
0 (0) 
S-cobalamin (<100 or <150 pmol/l) d 8 (12) 
B-folate (<305 nmol/l) 7 (10) 
S-25-OH-vitamin-D (<25 nmol/l) 35 (55) 
S-zinc (<10.7 πmol/l) 7 (11) 
≥1 micronutritional insufficiency 43 (68) 
≥1 micronutritional deficiency 48 (76) 
Abbreviations: n, numbers; HOMA, homeostatic model assessment; LDL, low density lipoprotein; HDL, high 
density lipoprotein; ALT, alanine aminotransferase.  
a As defined by the World Health Organization. 
b According to the Expert panel on integrated guidelines for cardiovascular health and risk reduction in children 
and adolescents 279. 
c According to Schwimmer et al 280 and Mårtensson et al 281.  
d Reference values according to Beckman Coulter Inc (DxI, low cut-off) and Roche Diagnostics (Modular 
E120, high cut-off). 
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Table 4. Psychiatric disorders, psychiatric medication, self-reported suicide attempts, mental health and health-
related quality of life in n=165 young adult (16-25 years) treatment-seekers with severe obesity.  
Variable Treatment-seekers 
Psychiatric disorder, % (n)  
Depressive episode 13 (22) 
Anxiety disorder  12 (20) 
ADHD 13 (21) 
Dyslexia 20 (33) 
Other neurodevelopmental disorders  5 (8) 
Eating disorder not otherwise specified 1 (2) 
≥1 psychiatric disorder  29 (47) 
Medication for any psychiatric disorder, % (n)  21 (35) 
Suicide attempts, % (n)  
Never 88 (145) 
>1 year ago 9 (15) 
<1 year ago 3 (5) 
HADS Anxiety subscale, total score; mean (SD)   7.8 (4.6) 
Normal (score ≤7); n (%) 53 (87) 
Subclinical (score 8 to 10); n (%) 21 (35) 
Clinical (score ≥11); n (%) 26 (42) 
HADS Depression subscale, total score; mean (SD)   5.3 (4.1) 
Normal (score ≤7); n (%) 73 (120) 
Subclinical (score 8 to 10); n (%) 17 (28) 
Clinical (score ≥11); n (%) 10 (17) 
Rosenberg Self-Esteem Scale, total score; mean (SD)   16.2 (6.9) 
Low self-esteem (score ≤15); n (%) 42 (69) 
Obesity-related Problems scale, total score; mean (SD)   63.7 (28.1) 
Mild impairment (score ≤39); n (%) 19 (32) 
Moderate impairment (score 40 to 59); n (%) 25 (42) 
Severe impairment (score ≥60); n (%) 55 (91) 
Positive screening for ADHD using ASRS; n (%) 37 (61) 
Short Form Health Survey-36  
Physical component score; mean (SD)   45.7 (11.2) 
Mental component score; mean (SD)   35.8 (13.9) 
Abbreviations: n, numbers; ADHD, Attention deficit hyperactivity disorder; HADS, Hospital Anxiety and 
Depression Scale; SD, standard deviation; ASRS, adult ADHD self-report scale. 
 
Treatment-seekers displayed more mental distress than the population controls with obesity 
class I or severe obesity as measured by GHQ-12 (Likert scoring: 14.9 points in treatment-
seekers vs 11.5 points in controls with obesity class I and 10.2 points in controls with severe 
obesity; GHQ scoring: 3.8 points vs 2.3 and 2.1 points, all, p ≤0.017 when adjusting for age, 
gender, socioeconomic status and BMI). Treatment-seekers also displayed more anxiety 
symptomatology (as measured by the EQ-5D anxiety item) compared to controls with class I 
obesity (RR=1.78, 95% CI: 1.33-2.38) or severe obesity (RR=1.71, 95% CI: 1.28-2.30). The 
frequencies of depression, suicidal ideation and suicide attempts did not display any 
statistically significant differences across patient vs control groups (all, p ≥0.33). 
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Table 5. Mental distress as measured by the General Health Questionnaire-12, depression; lifetime suicidal 
behavior; quality of life; and present physical/psychosomatic symptoms in n=121 young adults (18–25 years) 
seeking behavioral weight reduction treatment for severe obesity and n=363 normal weight controls (18-25 
years) from the Stockholm Public Health Survey, matched individually in a 1:3 ratio for age, gender and 
socioeconomic status. 
Variable Treatment-
seekers 
Population 
controls  
Difference or  
RR (95% CI) a 
General Health Questionnaire    
GHQ-12 (Likert scoring b), mean (SE) 15.5 (0.57) 10.8 (0.34) 4.55 (3.24, 5.86) 
GHQ-12 (GHQ scoring c), mean (SE) 3.9 (0.30) 2.2 (0.17) 1.75 (1.08, 2.42) 
Mental distress (GHQ scoring ≥3), % (n) 52 (63) 30 (109) 1.76 (1.38, 2.24) 
Positive responses to GHQ-12-items: % (n)    
‘Able to concentrate’ 67 (81) 80 (287) 0.83 (0.72, 0.94) 
‘Lost much sleep’ 27 (33) 19 (68) 1.56 (1.07, 2.26) 
‘Playing a useful part’ 63 (76) 81 (292) 0.78 (0.67, 0.91) 
‘Capable of making decisions’ 81 (98) 91 (328) 0.90 (0.82, 0.99) 
‘Under strain’ 34 (41) 25 (89) 1.37 (0.99, 1.89) 
‘Could not overcome difficulties’ 36 (43) 23 (84) 1.53 (1.12, 2.08) 
‘Enjoy normal activities’ 63 (76) 83 (297) 0.78 (0.67, 0.90) 
‘Able to face up to problems’ 70 (81) 86 (309) 0.85 (0.67, 0.98) 
‘Feeling unhappy and depressed’ 40 (48) 26 (92) 1.53 (1.13, 2.08) 
‘Losing confidence in yourself’ 35 (42) 17 (60) 2.26 (1.59, 3.21) 
‘Thinking of self as a worthless person’ 37 (45) 15 (54) 2.81 (1.97, 4.01) 
 ‘Feeling reasonably happy’ 64 (77) 85 (308) 0.74 (0.64, 0.85) 
Depression d, % (n)  22 (32) 8 (27) 2.18 (1.34, 3.55) 
Suicidal ideation, % (n) 41 (50) 19 (69) 1.98 (1.43, 2.73) 
Suicide attempt, % (n) 12 (14) 6 (20) 2.04 (1.06, 3.95) 
EQ5D, mean (SE) 0.64 (0.019) 0.86 (0.011) -0.23 (-0.27, -0.18) 
Some or extreme problems with: % (n)    
Mobility 22 (26) 4 (14) 6.61 (3.15, 13.84) 
Hygiene 3 (3) 1 (2) 2.91 (0.54, 15.81) 
Daily activities 32 (39) 6 (22) 5.70 (3.27, 9.90) 
Pain 68 (82) 30 (109) 2.17 (1.75, 2.68) 
Anxiety 85 (103) 42 (149) 1.97 (1.69, 2.29) 
Physical/psychosomatic symptoms: % (n)    
Headache 59 (71)  38 (138) 1.59 (1.29, 1.95) 
Hyperacusis  33 (40) 14 (51) 2.19 (1.51, 3.19) 
Urinary incontinence  16 (20) 6 (21) 2.74 (1.44, 5.23) 
Acid reflux  41 (49)  14 (50) 2.95 (2.02, 4.30) 
Fatigue  79 (95)  43 (155) 1.80 (1.53, 2.12) 
Tinnitus  26 (31) 21 (74) 1.10 (0.75, 1.61) 
Abbreviations: GHQ-12, General Health Questionnaire-12; RR, relative risk; SE, standard error. 
a Matched and adjusted for age, gender, socioeconomic status, tobacco smoking, hazardous alcohol drinking, 
physical disease, sexual orientation and social support. 
b Min–max (0–36). 
c Min–max (0–12). 
d Self-reported lifetime physician-diagnosed depression.  
 
6.2 RESULTS OF ASPECTS OF TREATMENT / RESEARCH QUESTIONS 4-5 
(STUDIES III-IV)  
Participants’ characteristics in Study III 
A total of n=3,531 young (18-25 years) and n=17,137 older (≥26 years) adult RYGB patients 
from SOReg, frequency matched for gender, BMI and year of surgery, were included in 
Study III. In the young adult age group, mean age was 22.2 years (SD: 2.1), 81.6% (n=2,882) 
were women and mean BMI was 43.7 kg/m2 (SD: 5.4). In the older adult age group, mean 
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age was 42.6 years (SD: 9.6), the age range was 26-74 years, 82.0% (n= 14052) were women 
and mean BMI was 43.4 kg/m2 (SD: 5.0). No clinically relevant differences were observed in 
matching variables between matching groups, although there was a statistically significant 
difference in BMI between groups (p <0.001). A total of n=369 young (37.0% of eligible) 
and n=2,210 older (46.1%) adults were included in the 5-year analysis. See flow chart in 
Figure 5 for details. 
Both young and older adults with complete data displayed higher baseline BMI (44.5 kg/m2 
vs 43.6 kg/m2 in young adults, 43.8 kg/m2 vs 43.3 kg/m2 in older adults) and fewer 
comorbidities than those with missing data at 5 years (15.2% vs 23.1% in young adults, 
44.0% vs 54.1% in older adults). Among older adults, smoking was more common (18.6% vs 
13.7%), and age was higher (43.2 years vs 42.5 years) in completers vs those with missing 
data (all, p <0.01).  
Weight loss  
Young adult completers lost less weight during the preoperative low-calorie diet period than 
older adult completers (5.2% vs 5.6% of preoperative weight, p <0.001). In the subsequent 
follow-ups, young adult completers displayed higher percentage weight loss and a more 
pronounced change in BMI slope than older adult completers up to 5 years post-RYGB in 
crude and adjusted (for gender, year of surgery, comorbidity at baseline [yes/no], surgical 
access [laparoscopic/open], duration of surgery [minutes], surgical volume [high/low] and 
concurrent surgery [yes/no]) analyses, all, p <0.001 (Tables 6-7 and Figure 7). A sensitivity 
analysis on percentage weight loss and change in BMI slope with listwise deletion data and 
last observation carried forward data supported our results (all, adjusted with the above 
mentioned co-variates, p <0.05) while the analysis with baseline carried forward data 
displayed lower percentage weight loss in young vs older adults at 1 (28.0% vs 28.6%), 2 
(19.3% vs 20.5%) and 5 (11.5 vs 13.1%) years after RYGB compared to baseline (all, 
adjusted with the above mentioned co-variates, p <0.05). The mixed models analysis with 
baseline carried forward data displayed no statistically significant difference in change in 
BMI slope between young and older adults (Table 7).  
Five years post-RYGB, EWL was higher (75.6% [SD: 27.2] vs 68.2% [SD: 25.9], and 
successful weight loss (EWL ≥50%) was more common (85.6% vs 76.0%) in young 
compared to older adult completers (both, crude, p <0.001, Table 6).   
 
 
 
 
 
 
 
 40 
Table 6. Body weight, body weight lost and excessive weight loss 1, 2 and 5 years after Roux-en-Y gastric 
bypass a in 3,531 young (18-25 years) and 17,137 older (26-74 years) adults matched for body mass index, 
gender and year of surgery. 
 1 year 2 years 5 years 
 Young 
adult 
(n=2,900) 
Older  
adult 
(n=15,298) 
Young 
adult 
(n=1,831) 
Older  
adult 
(n=9,959) 
Young 
adult 
(n=369) 
Older  
adult 
(n=2,210) 
Body weight, kg; mean 
(SD) 
82.7  
(16.9) 
83.3  
(16.1) 
81.5  
(16.7) 
82.4  
(16.5) * 
87.1  
(19.0) 
88.7  
(18.4) 
BWL, %, mean (SD) 34.6  
(7.6) 
32.0  
(7.5) **  
35.4  
(8.5) 
32.6  
(8.8) **  
31.8 
(10.5) 
28.2 
(10.1) **  
BWL category, % (n)        
Weight gain 0.0  
(1) 
0.0  
(2) 
0.0  
(2) 
0.1 
(11) 
0.5  
(2) 
0.5  
(11) 
0.0-14.9% BWL 1.3  
(37) 
1.4  
(212) 
1.7  
(31) 
2.5  
(251) * 
7.6  
(28) 
9.1  
(202) 
15.0-29.9% BWL 24.4  
(709) 
37.4  
(5,716) ** 
22.1  
(405) 
33.8  
(3,771) ** 
28.7  
(106) 
45.4  
(1,004) ** 
30.0-39.9% BWL 50.6  
(1,468) 
46.6  
(7,127) ** 
43.7 
(800) 
43.0  
(4,286) 
42.5  
(157) 
32.9  
(727) ** 
≥40.0% BWL 23.6  
(685) 
14.6  
(2,241) ** 
32.3  
(592) 
20.5  
(2,040) ** 
20.6  
(76) 
12.0  
(266) 
BMI <25 kg/m2, % (n) 23.3  
(675) 
15.8  
(2,416) ** 
27.6  
(505) 
19.5  
(1,938) ** 
16.3  
(60) 
10.0  
(221) ** 
%EWL, mean (SD) 84.2  
(22.2) 
78.7  
(21.7) ** 
85.7  
(23.1) 
79.9  
(23.3) ** 
75.6 
(27.2) 
68.2  
(25.9) ** 
EWL ≥50%, % (n) 94.3  
(2,734) 
92.0  
(14,059) ** 
93.4  
(1,708) 
90.3  
(8,973) ** 
85.6 
(316) 
76.0  
(1,680) ** 
Abbreviations: n, number; SD, standard deviation; BWL, body weight lost; BMI, body mass index; EWL, 
excessive weight loss. 
a Compared to preoperative weight (approximately 4 weeks before surgery including 2-3 weeks of low calorie 
diet).  
* p <0.05 for difference in young vs older adults. 
** p ≤0.001 for difference in young vs older adults. 
 
Table 7. Effects of matching group in 998 young adults (18-25 years) and 4,792 older (26-74 years) adults 
(patients eligible for 5-year follow up within the study period); on the intercept and the slope of body mass index 
5 years after Roux-en-Y gastric bypass for completers (full information maximum likelihood), in listwise 
deletion (LiDe), and when imputing data by using baseline carried forward (BCF) and last observation carried 
forward (LOCF). Matching groups were adjusted for gender, year of surgery, comorbidity (yes/no), surgical 
access (laparoscopic/open), duration of surgery (minutes), surgical volume (low/high) and concurrent surgery. 
 
 
a NYoung adults=232, NOlder adults=1525 
b Predicted body mass index at baseline for older adults.  
c Predicted change in body mass index per month for older adults.   
 
 
 
Parameter/effect Completers p-value LiDe a p-value BCF p-value LOCF p-value 
Intercept-intercept b 40.8 <0.001 39.9 <0.001 39.7 <0.001 41.7 <0.001 
Slope-intercept c -0.53 <0.001 -0.22 <0.001 -0.21 <0.001 -0.23 <0.001 
Young adults on 
intercept 
0.49 <0.001 0.55 0.002 0.29 <0.001 0.35 <0.001 
Young adults on slope -0.077 <0.001 -0.051 <0.001 0.0094 0.062 -0.011 <0.001 
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Figure 7. Body mass index in young (18-25 years) and older (26-74 years) adults before surgery / low calorie 
diet and 1, 2 and 5 years after Roux-en-Y gastric bypass. 
  
Abbreviations: LCD, low calorie diet. 
NYoung adults: Before LCD = 3,531, 1 year = 2,900, 2 years = 1,831, 5 years = 369. 
NOlder adults: Before LCD = 17,137, 1 year = 15,298, 2 years = 9,959, 5 years = 2,210. 
* p <0.05 unadjusted and when adjusted for body mass index at baseline, gender, year of surgery, comorbidity 
(yes/no), surgical access (laparoscopic/open), duration of surgery, surgical volume and concurrent surgery.  
 
Adverse events 
Figure 8 displays percentages of adverse events (any/significant/serious) in young and older 
adults, respectively. Intraoperatively and between 0 to 6 weeks after surgery, adverse events 
of any kind were less frequent in young vs older adults (OR=0.74, 95% CI: 0.58-0.93 and 
OR=0.79, 95% CI: 0.69-0.92 respectively). However, when adjusted for co-variates (baseline 
BMI, gender, year of surgery, comorbidity at baseline [yes/no], surgical access 
[laparoscopic/open], duration of surgery [minutes] and centre volume [low/high]), there was 
no significant difference between groups in percentages of adverse events of any kind 
intraoperatively (adjusted OR=0.87, 95% CI: 0.68-1.12) or at 6 weeks (OR=0.91, 95% CI: 
0.79-1.06). At the subsequent follow-ups, young adults reported higher rates of any type of 
adverse events between 6 weeks and 1 year (adjusted OR=1.45, 95% CI: 1.24-1.70), between 
1 and 2 years (adjusted OR=1.40, 95% CI: 1.18-1.66) and between 2 and 5 years (adjusted 
OR=1.72, 95% CI: 1.29-2.30) in crude and adjusted values, all, p <0.001 than older adults. 
See Figure 8 for crude data including p-values for adjusted analyses.  
The frequency of significant adverse events (Clavien Dindo 2-3a) was the same in young and 
older adults throughout the study period (all, p ≥0.20) independent of adjustment for 
covariates. For short-term serious adverse events (between surgery and 6 weeks post-RYGB), 
young adults displayed fewer adverse events than older adults (crude OR=0.73, 95% CI: 
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0.56-0.95, and adjusted OR=0.76, 95% CI: 0.58-1.00). However, young adults displayed 
more long-term serious adverse events (Clavien Dindo ≥3b) in crude and adjusted values 
between 6 weeks and 1 year (adjusted OR=1.71, 95% CI: 1.36-2.13), between 1 and 2 years 
(adjusted OR=1.44, 95% CI: 1.15-1.80) and between 2 and 5 years (adjusted OR=2.06, 95% 
CI: 1.45-2.92), all, p <0.001 than the older adults.  
When including all eligible (for 2- and 5 years follow-up) baseline patients in an intention-to-
treat analysis of any adverse events between the same assessment points as above, the results 
of fewer short-term (crude data) but more any adverse events (crude and adjusted data) in the 
young were attenuated but still significant (data not shown). For serious adverse events, the 
2-year data were borderline significant (p=0.062) while the 1- and 5-year data were 
significant. 
However, when analyzing completers (i.e. only those with 5-year data) with at least one 
adverse event of any kind between baseline (intraoperatively) and 5 years post-RYGB in 
completers, we found no difference between young and older adults in crude or adjusted 
values (24.5% vs 24.5%, p=0.97; adjusted OR=1.12, 95% CI: 0.95-1.32, p=0.18).  
In a classification of specified adverse events between matching groups, ileus (2.7% vs 1.5% 
at 6 weeks - 1 year, 5.0% vs 3.0% at 1-2 years and 10.3% vs 5.0% at 2-5 years) and “other 
adverse events” (3.4% vs 2.1% between 6 weeks and 1 year, 3.7% vs 2.4% between 1 and 2 
years and 7.9% vs 3.6% between 2 and 5 years) were more common in young adults, while 
hernia was more common in older adults (0.1% vs 0.5% between 6 weeks and 1 year, 0.3% 
vs 0.8% between 1 and 2 years and 0.3% vs 1.9% between 2 and 5 years), all p<0.05.  
Loss-to-follow-up 
Young adults consistently displayed higher risks for “missed appointment” (adjusted range of 
RR=1.25-2.13) and “total loss-to-follow-up” (adjusted range of RR=1.16-1.89; all, p <0.001) 
compared to older adults at all assessments throughout the observation period of 5 years. 
Moreover, younger patients were less often contacted for follow-up appointments 1 to 5 years 
post-RYGB (adjusted range of RR=1.18-1.50, all, p ≤0.010). Detailed data on loss-to-follow-
up are displayed in Table 8. Adjusted values were not materially different from crude values. 
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Figure 8. Percentage of any, significant (Clavien-Dindo 2-3a = complication requiring pharmacological 
treatment or intervention under local anesthesia) and serious (Clavien-Dindo ≥3b = complication requiring 
intervention under general anesthesia) adverse event in young (18-25 years) and older (26-74 years) adults 
intraoperatively, between surgery - 6 weeks, between 6 weeks - 1 year, between 1-2 years and between 2-5 years 
after Roux-en-Y gastric bypass. Error bars represent 95% confidence intervals. 
 
a NYoung adults intraoperatively=3,531, 6 weeks=3,328, 1 year=2,900, 2 years=1,830, 5 years=369.  
NOlder adults intraoperatively=17,137, 6 weeks=16,630, 1 year=15,280, 2 years=9,946, 5 years=2,210. 
b Registrations only after May 1, 2010: Nyoung adults6 weeks=2,657, 1 year=2,601, 2 years=1,734,  
5 years=369. Nolder adults6 weeks=13,288, 1 year=13,422 2 years=9,575, 5 years=2,202. 
* p <0.05 when adjusted for body mass index at baseline, gender, year of surgery, comorbidity at baseline, 
surgical access (laparoscopic/open), duration of surgery, center volume (low/high). 
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Table 8. Relative risk of loss-to-follow-up (missed appointment, no attempt to contact patient and total loss-to-
follow-up) at 6 weeks, 1, 2 and 5 years after Roux-en-Y gastric bypass in 3,531 young (18-25 years) compared 
to 17,137 older (26-74 years) adults matched for body mass index at baseline, gender and year of surgery.  
 Young adult Older adult Adjusted RR (95% CI),  
p-value a 
6 weeks, % (n)    
Visits 94.3 (3,328) 97.0 (16,631)  
Missed appointment b 5.0 (175) 2.2 (381) 2.13 (1.77-2.57), <0.001 
No attempt to contact patient  0.7 (23) 0.5 (94) 1.08 (0.68-1.71), 0.74 
Total loss-to-follow-up c 5.7 (203) 3.0 (506) 1.89 (1.60-2.23), <0.001 
1 year, % (n)    
Visits 82.1 (2,900) 89.3 (15,298)  
Missed appointment b 12.2 (430) 6.3 (1,088) 1.81 (1.62-2.02), <0.001 
No attempt to contact patient  4.2 (149) 2.4 (413) 1.50 (1.24-1.81), <0.001 
Total loss-to-follow-up c 17.9 (631) 10.7 (1,839) 1.57 (1.44-1.71), <0.001 
2 years, % (n) d    
Visits 55.7 (1,831)  62.5 (9,959)  
Missed appointment b 19.2 (632) 12.3 (1,965) 1.47 (1.36-1.60), <0.001 
No attempt to contact patient  11.6 (381) 9.7 (1,544) 1.18 (1.06-1.31), 0.002 
Total loss-to-follow-up c 44.3 (1,458) 37.5 (5,975) 1.20 (1.15-1.25), <0.001 
5 years, % (n) d    
Visits 37.0 (369)  46.1 (2,210)  
Missed appointment b 25.8 (257) 19.9 (955) 1.25 (1.11-1.40), <0.001 
No attempt to contact patient  9.5 (95) 6.5 (311) 1.33 (1.07-1.65), 0.010 
Total loss-to-follow-up c 63.0 (629)   53.9 (2,582) 1.16 (1.10-1.23), <0.001 
Abbreviations: RR, relative risk; CI, confidence interval; n, numbers. 
a  Adjusted for body mass index at baseline, gender, year of surgery, comorbidity at baseline, surgical access 
(laparoscopic/open), duration of surgery, center volume (low/high). 
b Patient was contacted by care provider but did not turn up at planned appointment. 
c “Missed appointment”, “no attempt to contact patient”, loss-to-follow-up of unknown reason (=missing data) 
and deceased.  
d Includes only patients who were eligible for follow-up at 2 years (nyoung adults = 3,289, nolder adults = 15,934) and  
5 years (nyoung adults = 998, nolder adults = 4,792). 
 
Participants’ characteristics in Study IV 
A total of n=2,542 young (18-25 years) and n=12,425 older (≥26 years) adult RYGB patients 
from Study III were included in Study IV. In the young adult age group, mean age was 22.2 
years (SD: 2.2), 82.1% (n=2,087) were women and mean BMI was 43.6 kg/m2 (SD: 5.4). In 
the older adult age group, mean age was 42.6 years (SD: 9.6), the age range was 26-74 years, 
81.9% (n=10,177) were women and mean BMI was 43.4 kg/m2 (SD: 5.0).  
Concerning differences in baseline variables among patients from the SOReg cohort (in 
Study III) with vs without HRQL data at baseline (included vs non-included in Study IV), 
there were fewer smokers (13.4% vs 15.0%), more patients with depression (15.8% vs 
14.5%) and more open procedures (3.9% vs 2.8%) among included vs non-included older 
adults, while no differences were found between included/non-included young adults.    
A total of n=138 young (20.7% of eligible) and n=1,021 older (31.8%) adults were included 
in the 5-year analysis (see flowchart in Figure 6). A missing data analysis revealed 
statistically significant differences in baseline descriptives between those with missing vs 
those with complete data at the 5-year follow-up (for young adults: laparoscopic access: 
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98.2% vs 94.2%; for older adults: 42.5 years old vs 43.8 years old at baseline; 168.1 cm vs 
167.5 cm; 18.4% vs 14.6% men; any comorbidity: 53.7% vs 45.2%; sleep apnea: 10.2% vs 
8.2%; laparoscopic access: 85.7% vs 97.1%; all, p <0.05). Also, HRQL-baseline levels were 
lower in missing vs complete data for certain variables in young (physical function, social 
function, physical component score) and older adults (physical role, bodily pain, general 
health, vitality, social function, physical component scare and OP) all, p <0.05. In Study IV 
5-year weight loss in young and older adults were 32.3% and 27.6% respectively (p <0.001).  
Health-related quality of life 
A total of 70.8% (n=1,793) of young and 63.5% (n=7,874) of older adults were categorized 
as having severely impaired psychosocial functioning (OP score) at baseline (p <0.001). Five 
years after RYGB, young adults displayed average to large improvements (ES ≥0.5) in 
physical functioning, physical component score and OP, while older adults displayed average 
to large (ES ≥0.5) improvements in physical functioning, role physical, general health, 
physical component score and OP as presented in Table 9-10 (all, p ≤0.001). Concerning the 
mental domains of SF-36; weak, negligible or no 5-year changes were observed in any of the 
age groups as presented in Table 10 (all, p <0.55).  
Table 9. Physical domains of Short Form-36 and between-groups effect sizes up to 5 years after Roux-en-Y 
gastric bypass in n=2,542 young (18-25 years) vs n=12,425 older (26-74 years) adults. 
Variable, mean (SD) Young adult Older adult p-value a Effect size a 
Physical functioning, baseline 64.7 (20.7) 58.5 (22.6) <0.001 0.15 
1 year  93.0 (14.3) ** 88.4 (18.0) **  <0.001 0.28 
2 years  91.8 (14.5) ** 87.7 (19.1) ** <0.001 0.24 
5 years  87.1 (17.2) ** 81.5 (22.9) ** 0.027 0.28 
Effect size (baseline - 5 years) 1.18 1.01   
Role physical, baseline 59.1 (37.5) 55.3 (39.6) <0.001 0.10 
1 year  90.7 (23.9) ** 86.6 (29.6) ** <0.001 0.15 
2 years 85.7 (30.0) ** 84.0 (32.3) ** 0.835 0.05 
5 years  74.2 (38.8) * 75.7 (37.7) ** 0.647 0.04 
Effect size (baseline - 5 years) 0.40 0.53   
Bodily pain, baseline 61.0 (27.4) 52.6 (27.5) <0.001 0.63 
1 year  80.8 (24.5) ** 74.1 (28.0) ** <0.001 0.25 
2 years  75.3 (28.1) ** 72.0 (29.2) ** 0.006 0.12 
5 years  68.1 (34.0) * 63.0 (31.5) ** 0.071 0.16 
Effect size (baseline - 5 years) 0.06 0.35   
General health, baseline 52.2 (22.3) 54.7 (22.2) <0.001 0.11 
1 year  77.7 (19.0) ** 79.3 (20.3) ** <0.001 0.08 
2 years  73.1 (22.3) * 76.1 (22.2) ** <0.001 0.13 
5 years  61.7 (25.8) ** 66.5 (25.2) ** 0.039 0.19 
Effect size (baseline - 5 years) 0.39 0.50   
Physical component score, baseline 40.7 (10.0) ** 36.8 (10.9) <0.001 0.37 
1 year  53.4 (7.1) ** 50.7 (9.3) ** <0.001 0.33 
2 years  52.2 (8.3) ** 50.2 (9.8) ** <0.001 0.22 
5 years  47.1 (11.3) ** 45.3 (12.4) ** 0.171 0.15 
Effect size (baseline - 5 years) 0.60 0.73   
Abbreviations: SD, standard deviation. 
Nyoung adults=1,440 (1 year), 777 (2 years), 138 (5 years). 
Nolder adults=8,487 (1 year), 4,816 (2 years), 1,021 (5 years). 
Effect size categories: negligible (<0.2), weak (0.2-0.5), average (0.5-0.8), large (>0.8). 
a Between-group differences.  
** Within-group difference compared to baseline, p ≤0.001  
* Within-group difference compared to baseline, p <0.05 
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Table 10. Mental domains of Short Form-36, Obesity-related Problems scale and between-groups effect sizes up 
to 5 years after Roux-en-Y gastric bypass in n=2,542 young (18-25 years) vs n=12,425 older (26-74 years) 
adults. 
Variable, mean (SD) Young adult Older adult p-value a Effect size a 
Vitality, baseline 42.9 (21.8) 44.3 (23.4) <0.001 0.06 
1 year  64.6 (21.7) ** 67.9 (23.6) ** <0.001 0.15 
2 years  57.8 (24.8) ** 63.1 (25.4) ** <0.001 0.21 
5 years  48.1 (27.3)  52.1 (27.2) ** 0.118 0.15 
Effect size (baseline - 5 years) 0.21 0.31   
Social functioning, baseline 67.5 (27.7) 70.9 (27.8) <0.001 0.12 
1 year  86.4 (21.1) ** 87.4 (21.5) ** <0.001 0.05 
2 years  81.6 (24.1) ** 84.7 (23.6) ** 0.001 0.13 
5 years  73.9 (29.1)  77.3 (27.5) ** 0.203 0.12 
Effect size (baseline - 5 years) 0.23 0.23   
Role emotional, baseline 63.6 (40.4) 71.8 (38.5) <0.001 0.21 
1 year  81.8 (33.8) ** 85.5 (31.3) ** <0.001 0.11 
2 years  77.6 (36.4) ** 82.2 (34.3) ** 0.001 0.13 
5 years  70.6 (41.1) 73.8 (39.8) 0.426 0.08 
Effect size (baseline - 5 years) 0.17 0.05   
Mental health, baseline 62.7 (20.6) 69.2 (20.5) <0.001 0.32 
1 year  75.9 (19.7) ** 79.8 (19.9) ** <0.001 0.20 
2 years  71.1 (22.1) ** 76.7 (21.7) ** <0.001 0.26 
5 years  68.2 (22.8) * 69.8 (23.9) 0.285 0.07 
Effect size (baseline - 5 years) 0.25 0.03   
Mental component score, baseline 40.7 (12.6) 45.4 (12.5) <0.001 0.37 
1 year  46.0 (12.1) ** 49.0 (12.0) ** <0.001 0.25 
2 years  43.5 (13.1) ** 47.2 (13.0) ** <0.001 0.28 
5 years  40.9 (14.0) 43.5 (14.4) ** 0.008 0.18 
Effect size (baseline - 5 years) 0.02 0.14   
Obesity-related Problems scale, median 
(IQR), baseline 
75.0 (33.3) 70.8 (35.7) <0.001 0.20 
1 year  20.8 (33.4) ** 12.5 (29.2) ** <0.001 0.34 
2 years  29.2 (45.9) ** 12.5 (33.3) ** <0.001 0.45 
5 years  39.6 (45.8) ** 20.8 (45.8) ** <0.001 0.40 
Effect size (baseline - 5 years) 1.11 1.34   
Abbreviations: SD, standard deviation; IQR, interquartile range. 
Nyoung adults=1,440 (1 year), 777 (2 years), 138 (5 years).  
Nolder adults=8,487 (1 year), 4,816 (2 years), 1,021 (5 years). 
Effect size categories: negligible (<0.2), weak (0.2-0.5), average (0.5-0.8), large (>0.8). 
a Between-group differences.  
** Within-group difference compared to baseline, p ≤0.001 
* Within-group difference compared to baseline, p <0.05 
 
Older adults displayed larger improvements in physical role, general health, vitality, social 
functioning, physical component score and OP than their younger counterparts as displayed 
in the multiple regression analysis of change (5 years post-RYGB vs baseline) in each of the 
HRQL components (all, adjusted p ≤0.036, Table 11). A sensitivity analysis that included 
baseline and last observation carried forward data did not materially alter these findings (data 
not shown). 
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Table 11. Effect of matching group (1=young adults) on 5-year change in Short Form-36 and Obesity-related 
Problems scale in n=138 young (18-25 years) and n=1,021 older (26-74 years) adults (i.e. eligible patients). 
Variable a Unadjusted model 
Beta (95% CI)  
p-value Adjusted model  
Beta (95% CI) b 
p-value  
Short Form-36     
Physical functioning -2.6 (-6.9, 1.8) 0.25 -2.0 (-5.5, 1.5) 0.27 
Physical role -9.0 (-17.7, -0.44) 0.039 -7.2 (-14.0, -0.47) 0.036 
Bodily pain -2.2 (-8.2, 3.8) 0.47 -2.0 (-7.4, 3.4) 0.47 
General health 0.72 (-4.3, 5.8) 0.78 -6.6 (-10.9, -2.3) 0.02 
Vitality -3.8 (-9.2, 1.7) 0.17 -6.2 (-10.9, -1.4) 0.011 
Social functioning -5.3 (-11.5, 0.90) 0.094 -5.7 (-11.0, -1.4) 0.026 
Role emotional 0.56 (-8.3, 9.5) 0.90 4.7 (-12.0, 2.7) 0.21 
Mental health 2.4 (-2.2, 7.0) 0.30 -1.3 (-5.4, 2.8) 0.54 
Physical component score -2.1 (-4.3, 0.064) 0.057 -2.1 (-4.0, -0.14) 0.036 
Mental component score 0.06 (-2.9, 3.0) 0.99 -2.04 (-4.7, 0.58) 0.13 
Obesity-related Problems scale 5.3 (-0.64, 11.3) 0.08 13.6 (8.7, 18.4) <0.001 
Abbreviations: CI, confidence interval. 
a For Short Form-36, a negative coefficient denotes that the change (5-year levels vs baseline) was smaller in 
young vs older adults. For Obesity-related Problems Scale, a positive coefficient denotes that the change was 
smaller in young vs older adults.  
b Adjusted for health-related quality of life component at baseline, comorbidity (yes/no), weight loss at five 
years, adverse events (yes/no) and surgical access (laparoscopic/open).  
  49 
7 DISCUSSION 
Here I will endeavor to address the five research questions stated above and place the results 
in the context of previous research to discuss clinical implications of the main findings and 
suggest areas for future research.   
 
7.1 MAIN FINDINGS ON CHARACTERIZATION (STUDIES I-II)   
We found that a total of 47-85% of young adult treatment-seekers to a specialized obesity 
unit had anxiety symptomatology, 27% had depressive symptomatology, 37% had ADHD 
symptomatology, 42% had low self-esteem, 12% had a history of suicide attempts, 55% had 
severe impairment in psychosocial functioning and 52% had mental distress. A total of 29% 
had ≥1 psychiatric diagnosis, including depression (13%), ADHD (13%) and other 
neurodevelopmental disorders (5%). We found plasma lipid abnormalities in 62%, insulin 
resistance in 82%, poor cardiorespiratory fitness in 92% and a micronutritional deficiency in 
48% of the treatment-seekers.  
The design of Study II allowed us to compare our results from treatment-seekers with those in 
population controls with different BMI levels. Herein, we found that the treatment-seekers 
experienced approximately doubled RR for mental distress, depression, anxiety and suicidal 
behavior compared to individually matched population controls. For physical/psychosomatic 
symptoms, including urinary incontinence and acid reflux, the RR almost tripled for 
treatment-seekers vs populations controls. We also found that treatment-seekers displayed 
significantly more mental distress and lower quality of life than population controls with class 
I obesity or severe obesity.  
Moreover, we found that anxiety symptomatology in treatment-seeking young adults with 
obesity was associated with pain and low self-esteem, while depressive symptomatology was 
associated with physical inactivity, low self-esteem and low psychosocial functioning. 
Other research:  
Mental health in young adults with obesity 
Although Study I was not designed to compare results with a control group, a review of 
reference literature indicates that compared to population data the participants in Study I 
display poor health, particularly in regard to mental health: Normative HADS scores for 
Swedish 16-23-year-olds were 3.8-7.0 for anxiety and 2.5-4.0 for depression (7.8 and 5.3 in 
Study I) 282, and normative SF-36 in the same study group was 52-55 (physical component 
score) and 39-51 (mental component score) (46 and 36 respectively in Study I) 282. Normative 
scores varied between genders and mode of response (email/telephone). Self-esteem as 
measured by RSES was higher (i.e. better) in U.S. reference controls (Swedish reference data 
were not found) than in the present study (22.3 vs 16.2 points) 283. A total of 15% of Swedish 
18- to 24-year old women and 10% of Swedish 18- to 24-year old men had been either 
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hospitalized in a psychiatric ward and/or prescribed psychiatric medication in 2016 (mainly 
for depression and anxiety) (extracted data) 284, which may be (non-statistically) compared 
with 21% on psychiatric medication in our patient group. Interestingly, a Swedish case 
control study on validation of GHQ-12 found that a Likert score ≥14 points and a GHQ score 
≥4 points discriminated well between healthy individuals and affective disorders 285. 
Accordingly, our data of 15.5 (SD: 0.57) using Likert scoring and 3.9 (SD: 0.30) using GHQ 
scoring in treatment-seekers highlight possible psychiatric distress in young adults with 
obesity that needs further evaluation.  
The few previously published studies on mental health in young adults with obesity also 
found a higher prevalence of mental distress (assessed via standardized psychiatric interview) 
in German treatment-seekers with obesity compared to population controls: 23% vs 10% for 
depression, and 40% vs 14% for anxiety 199. Meanwhile, 31.5% of American teenagers 
undergoing bariatric surgery had a psychiatric diagnosis 286, i.e. rates that were similar to the 
present findings.  
Despite a repetitive bidirectional relationship between obesity and mental distress, as 
discussed in the introductory chapter, the role of mediators, moderators and direct cause-
effect links between the two states continue to be obscure. Previous data generally proposed 
BMI to be repetitively positively associated with the level of mental distress (in contrast to 
the results of the regression analysis in Study I). Moreover, educational attainment, body 
image, binge eating, physical health and psychosocial characteristics such as self-esteem, 
hostility, anger, sadness and maladaptive schemas have been associated with both obesity and 
mental distress 287. Inflammation is suggested to be another mechanism through which 
obesity and depression may coexist 288. However, data on associations between obesity and 
mental distress have generally been cross-sectional, which does not reveal whether any of the 
above-mentioned correlates are possible targets in obesity care.  
Cardiometabolic health in young adults with obesity 
In addition to poor mental health indices, a majority of the treatment-seekers in our study 
displayed high-risk levels of cardiometabolic markers including lipid abnormalities, insulin 
resistance and elevated alanine aminotransferase levels. Previous prevalence studies of 
cardiometabolic risk markers in youth have generally included patients on waiting lists for 
bariatric surgery, i.e. patients who were generally worse off than those in behavioral 
treatment, and have reported levels that were similar to our results: The American Teen-
LABS consortium reported that 50.4% had dyslipidemia, 26.1% had impaired fasting 
glucose, 71.1% had increased HOMA levels and only 5.0% were free from any 
cardiovascular risk marker 289.  
In non-bariatric treatment-seeking cohorts, youths with severe obesity vs overweight 
displayed significantly more abnormal levels of lipids (58.5% of those with severe obesity vs 
45.8% of those with overweight), alanine aminotransferase (81.4% vs 55.4%) and insulin 
resistance (82.1% vs 55.6%) 170. Community studies found lower frequencies of 
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cardiometabolic risk factors in youth with severe obesity than is the case in the present thesis 
(dyslipidemia in 10.8-30.0%, abnormal levels of HbA1c in 13.2%); however, they found a 
clear positive association between the severity of obesity and cardiometabolic risk markers 
172. 
The present findings are serious given that cardiometabolic risk markers generally track into 
adulthood and severely increase the risk of future cardiovascular morbidity and mortality, 
independently of future BMI levels 290 291.  
Micronutritional deficiencies in young adults with obesity 
When comparing our results with data from a Danish population study of 18-to-25-year-olds 
(although not statistically tested), our results indicate that the treatment-seeking young adults 
in Study I suffer from lower vitamin D levels than Danish controls of different BMI levels 
(35% vs 19.3% had vitamin D deficiency, and 45% vs 30.1% had vitamin D insufficiency, 
using the same cut-offs) 292. The Danish study also found an association between poor 
vitamin D levels and obesity, as has been found in other age groups 292 293. Hypovitaminosis 
D has been linked to obesity via low dietary intake, increased uptake of vitamin D in the fat 
cells, low sun exposure and secondary low conversion to active vitamin D and reduced 
hepatic synthesis of vitamin D secondary to steatosis 294. Iron status was similar in our 
population as that in an Australian sample of 18- to 25-year old women with obesity, low 
ferritin levels (<15 µg/l) were found in 16.7%. The association between low iron levels and 
obesity has been explained by low dietary intake and the obese inflammatory state 295. 
Moreover, previous studies of obese populations showed disparate results regarding 
deficiencies in folate (0.0-63.2%) and vitamin B12 (5.1-20.0%) 296. Micronutritional 
abnormalities in young ages are of major concern given the associations with osteomalacia 
(hypovitaminosis D), cognitive deficits (hypoferremia) and fatal pregnancy outcomes (low 
folate), among others 297-299.  
 
7.2 MAIN FINDINGS ON ASPECTS ON TREATMENT (STUDIES III-IV)  
Five years after RYGB, we found statistically significantly more weight loss (31.8% vs 
28.2%), fewer short-term (in crude data) but more long-term (in crude and adjusted) adverse 
events (e.g. 20.3% vs 12.7% between 2 to 5 years post-surgery), higher loss-to-follow-up 
throughout (63.0% vs 53.9%) and generally smaller improvements in HRQL in young (18-25 
years) vs older (26-74 years) adults. Moreover, we found clinically relevant improvements in 
physical HRQL in young adults up to 5 years after RYGB, while their mental HRQL did not 
differ from baseline levels.  
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Other research:  
Age-dependent effects on weight loss 
Our findings of statistically significantly more weight loss in the young completers support 
previous publications that showed increased BMI loss 60 months post-RYGB in young (<35 
years) compared to older patients when grouped in age quartiles 300, and higher weight loss 2 
years after gastric banding in women aged 20-45 years old compared to 55-to-65-year-old 
women (about 10% more EWL) 301. Conversely, behavioral weight loss trials report less 
weight loss in young (<35 years) compared to older adults (≥35 years, 4.3 vs 7.7 kg, 6-month 
trial) 233. Given the poor weight loss in young adults in behavioral treatment (-2.4 kg 
according to a systematic review of up to 12 months follow-up) 235, our results clearly suggest 
that Roux-en-Y gastric bypass provides the most efficient weight loss treatment to date for 
this age group; this is also supported by the few and smaller previous studies of similar age 
groups 302.  
There are several plausible explanations for the favorable weight loss in the younger patients: 
redistribution in fat mass accumulation over the life course may change lipolysis and insulin 
regulation, and therefore also the potential for weight loss 301 303 304. For example, fat mass 
lost after RYGB was mainly found to consist of subcutaneous adipose tissue, which is more 
prevalent in younger ages 304. Furthermore, brown adipose tissue declines with age, possibly 
contributing to higher energy expenditure and thus favoring weight stability after RYGB in 
the young 305. Faria et al discussed that the age-effect is due to better glucose control or lower 
contamination by organic pollutants in the visceral fat in the young 306. Moreover, one study 
reported lower energy intake in young (<35 years) compared to older patients (≥35 years) 
after RYGB 307, which could contribute to the lower weight in the young post-RYGB. 
Hypothetically, obesity could differ in terms of genetics and metabolic activity in young 
compared to older adults secondary to earlier onset of obesity and/or shorter duration of being 
obese given the recent rise in obesity incidence during late adolescence 4 52, which together 
may influence energy expenditure post-RYGB. 
Although a statistical difference was found in weight loss between young and older adult 
completers, the clinical relevance of the difference is not obvious. Thus, our findings may not 
necessarily be used as an argument to advance RYGB-surgeries to as young ages as possible. 
Rather, the present results indicate that age seems to be a predictor to weight loss, and that 
young age does not exclude from surgery.  
Loss-to-follow-up is a common problem in obesity surgery research 308, meanwhile 
sensitivity analyses have seldom been used/reported for. The present findings on weight loss 
with different conclusions depending on which analysis we used (i.e. higher percentage 
weight loss in the older adults in the baseline carried forward analysis but the opposite in the 
other ones), highlight the need for reporting weight loss data by the usage of different 
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sensitivity analyses to make the analysis more transparent as long as follow-up is not 
complete. 
Age-dependent effects on adverse events 
Ageing was previously regarded as a risk factor for adverse events post-RYGB primarily in 
short-term studies 309. For example, Morgan et al reported a positive association between age 
as a linear variable and adverse events up to 1 year after RYGB in 31-to-54-year-olds 310. 
Possibly, the low numbers of young adults in the study by Morgan et al explain the 
divergence between theirs and our data, since the association between age and adverse events 
post-RYGB is not necessarily linear. Moreover, patients with unspecified adverse events 
were not recorded in the study by Morgan et al, leading to under-reporting of, for example, 
abdominal pain that required surgical exploration; in our study this would have been reported 
as a serious adverse event.  
In addition, we stratified adverse events by intraoperative events, 6 weeks, 1 year etc., while 
Morgan et al collapsed their data into one measurement (0-1 year). Although our study was 
not designed for collapsing all data on adverse events into one measurement period (since this 
allow for diverse and uncontrolled loss-to-follow-up between groups within the observation 
period), it is however notable that our results in the collapsed analysis did differ from the 
main analysis and showed no differences in number of adverse events in young vs older 
adults. Possibly, age influences the risk of adverse events differently in the short vs long-
term, with a higher risk of adverse events in older patients shortly after surgery (due to e.g. 
cardiovascular co-morbidities), and a higher risk of long-term adverse events in younger 
patients. If so, a comparatively high number of adverse events among the older patients 
shortly after surgery may impact on 1-year outcomes, which in that case could explain the 
diverging results between our study and that of Morgan et al with 1-year data. Aligning with 
this, age <50 years was found to be predictive of adverse events up to 30 days after bariatric 
surgery in a recent SOReg study 309. Furthermore, RYGB-related self-reported symptoms 
(surgical, medical, nutritional) leading to healthcare contact after surgery were more common 
in patients younger than 35 years of age in a Danish cohort with a median of 4.7 years follow-
up after surgery 311. Moreover, Stenberg et al showed that increasing age was negatively 
associated with small bowel obstruction 3 years after RYGB 312.  
Possibly, young adults’ psychological vulnerability may predispose to surgical exploration of 
undefined pain and thus higher frequencies of adverse events, since depression and stress 
have been linked to postoperative pain syndromes 313.   
Age-dependent effects on loss-to-follow-up 
Previous research on age as a predictor for adherence post-RYGB reports both negative 314 315 
and no 316 associations; however, comparisons of data are limited due to the heterogeneity of 
definitions of loss-to-follow-up between studies. Possibly, young adults’ preoccupation with 
peer sameness, low perception of future health hazards and an urge for living independent 
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lives, as well as frequent moves between houses/changing cities may predispose to higher 
loss-to-follow-up in young vs old 317 318. Interestingly, cognitive impairments and depressive 
symptoms, which are frequent in the obese young adult patient group, have been linked to 
low adherence 319-321. 
While a number of studies found positive associations between adherence and weight loss as 
well as lower complication rates 322 323, the importance of long-term follow-up, including 
effects on weight loss, adherence to dietary regimens and vitamin substitution is largely 
unknown. 
Health-related quality of life 
Physical and mental HRQL 1 year after RYGB in young as well as older adults in Study IV 
approached Swedish norm levels (physical component score: 53.4 [SD: 7.1] for young 
RYGB patients vs norm levels of 53.4 [SD: 6.8], and 50.7 [SD: 9.3] in older RYGB patients 
vs norm levels of 51.2 [SD: 8.5]; mental component score: 46.0 [SD: 12.1] in young RYGB 
patients vs norm levels of 49.8 [SD: 9.5], and 49.0 [SD: 12.0] in older RYGB patients vs 
norm levels of 50.2 [SD: 10.0]) but deteriorated below norm levels both 2 and 5 years after 
surgery. With the exception of studies on adolescent RYGB patients, HRQL has seldom been 
reported in detail for younger cohorts: In the Swedish AMOS study on 13-to-18-year-olds 
undergoing RYGB, the physical component score was improved 5 years after RYGB (48.3 at 
5 years vs 44.1 at baseline, p <0.001) while there was no statistically significant difference in 
mental component score (44.7 vs 41.6, p <0.66) 238. Studies that collapsed all patients ≥18 
years into one group generally found clear long-term improvements in physical HRQL while 
mental HRQL displayed diverging results 324.  
The few studies to date on the effect of age on changes in HRQL after RYGB reported an 
inverse association between age and physical function as well as bodily pain (both SF-36 
variables) 325. Possibly, poorer baseline physical function in the older participants may 
explain why previous data diverged from our results, since low HRQL levels allow for 
greater changes. Importantly, and aligning with the discussion on age-dependent effects on 
weight loss, the clinical relevance of the differences in HRQL between young and older 
adults is not clear.  
 
7.3 CLINICAL IMPLICATIONS  
Obesity care clearly involves not only weight loss per se, but also management of obesity-
related comorbidities and symptoms. However, traditional obesity care has focused on 
cardiovascular obesity-related diseases and may thus have dismissed other relevant aspects in 
the care of the young adult patient who has not yet developed such comorbidities. For 
example, symptoms such as urinary incontinence, fatigue and headache, found to be 
prevalent in Studies I-II, may affect young adults’ every-day life more than increased levels 
of lipids, glucose etc. and should thus be addressed by obesity professionals alongside 
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cardiovascular preventive efforts. Additionally, a change in perspective with more focus on 
present symptoms and less on future risks may increase young adults adherence to obesity 
care, since young adults generally search weight loss treatment primarily for psychosocial 
reasons while future cardiovascular diseases are of little motivational value 234. 
Coexisting obesity and mental distress in young adults – a challenge for healthcare 
Although there is not yet any straightforward explanation as to why obesity and mental 
distress co-occur, we know from research and clinical practice that treating mental distress 
may influence weight status and vice versa. For example, eating may relieve mental distress 
326 and thus weight gain will continue as long as the stressors are not appropriately targeted. 
This is why a thorough mental health examination is essential when initiating a weight loss 
program. High levels of mental distress have the potential to impair treatment outcomes 
because successful behavioral treatment relies upon cognitive restraint which, in turn, is 
dependent on mental well-being. Therefore, obesity professionals should pay continuous 
attention to signs of mental distress and the severity of pre-existing mental illness throughout 
the treatment period. This is particularly important given that the incidence of mental illness 
peaks during young adulthood and pre-symptomatology (for example undefined anxiety) may 
therefore develop during treatment (to a defined psychiatric disease) which in turn may 
impact upon obesity treatment 138. Moreover, weight gain is a common side effect of 
psychiatric medications 224, which may lead to undertreatment of psychiatric diseases in 
patients with obesity which, in turn, may impair weight management further.  
Importantly, obesity and mental illness were together highlighted as the two main public 
health issues and challenges in Sweden in 2017 30. Pinpointing shared phenomenological 
characteristics, such as physical inactivity (as were shown to co-vary with mental distress in 
Study I), overeating (as in atypical depression) and sleep disturbances may constitute one 
way of treating both diseases simultaneously 327. Likewise, pinpointing shared external 
factors in preventive efforts, such as poor socioeconomic status, unemployment and stigma 
may target obesity as well as mental distress at the same time, and thus serve as another way 
of handling obesity and mental issues. In addition, evidence is emerging that both depression 
and obesity improve when treated with naltrexone/bupropion, and may help when treating 
both disorders 328. However, the question of how to handle comorbid obesity and mental 
distress is clearly challenging in today’s healthcare organization, because psychiatry and 
obesity professionals seldom operate in the same clinic. 
Given the high prevalence of both obesity and mental distress, the two may co-occur by 
chance 222. If so, we cannot expect accompanying mental health problems to improve directly 
secondary to weight loss, as opposed to cardiovascular obesity-related comorbidities (as 
observed in the lack of long-term improvements in mental HRQL in Study IV despite 
profound weight loss) 327. Likewise, weight loss may not necessarily follow mental health 
improvements. Instead, standard care treatment of both mental health problems and obesity 
together with knowledge on how pharmacotherapy impacts on weight status is probably 
necessary in order to improve the overall health of these patients.  
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Given that an increasing amount of evidence supports increasing levels of psychiatric adverse 
events post-RYGB, particularly in young adults with previous mental ill-health 114,  the 
present findings of high levels of mental distress in treatment-seekers clearly call for 
attention, and support a thorough mental health examination before referral to bariatric 
centers, together with close follow-up after surgery. Whether the follow-up should be part of 
standard surgical follow-up, or part of routine psychiatric/general practice is however not as 
clear, since data have so far not revealed whether bariatric surgery directly affects mental 
health or whether the results are due to cohort effects, given the lack of controlled studies.  
Importantly, although mental distress is frequent in young adults with obesity, obesity per se 
in this age groups does not automatically implicate mental health problems in all patients. To 
falsely apply mental distress on patients secondary to their physical appearance may be 
counterproductive and cause stigma as discussed by Brandheim 329. 
Bariatric surgery or not, and when is the right time to intervene? 
The increasing rates of obesity in young adulthood, together with the clear augmented risks 
of future cardiovascular disease and premature death in this age group, is not only of 
clinical but also of major societal concern, given the high socioeconomic burden of long-
standing obesity. Effective treatment is therefore highly warranted and bariatric surgery is 
clearly the most effective weight loss treatment to date with secondary positive effects such 
as less pain and improved physical function. However, the potential concomitant increased 
risks of surgical (particularly long-term, as displayed in Study III), micronutritional and 
psychiatric (as found in previous studies) adverse events constitute major drawbacks, 
creating a considerable treatment dilemma for clinicians. If the young adult is offered solely 
lifestyle modification, obesity is likely to continue. Meanwhile, bariatric surgery is 
associated with worsened mental health status (importantly, research does not yet show a 
clear cause-effect relationship), for some with fatal outcomes, or leads to even more serious 
micronutritional deficiencies than those observed before surgery.  
It is reasonable to hypothesize that improved follow-up of patients after surgery may 
overcome aspects of these fears, although there is not yet enough scientific evidence to 
support this. Enhanced follow-up could, for example, include multidiscipline assessments 
including repetitive blood tests for micronutritional deficiencies and thorough mental health 
assessments by psychiatrists. Whether intensified follow-up regimens could counteract 
surgical adverse events is however less obvious. Importantly, and in light of the findings in 
the present thesis, cognitive impairment and depression have been associated with poor 
adherence post-RYGB 320, and should be targeted when designing post-bariatric care 
programs for young adults. 
The lack of long-term quantitative and qualitative data on bariatric surgery in young adults is 
a concern given that young adults differ in terms of brain and psychosocial maturity as well 
as psychological vulnerability from their older counterparts, on whom the long-term bariatric 
studies in general so far have been conducted 103. Meanwhile, young adults are pushed 
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towards bariatric surgery because behavioral treatment requires continuous effort. The pros 
and cons of bariatric surgery for young adults therefore warrant reflection and individualized, 
patient-centered timely decisions; this poses a clear challenge for the clinician while bariatric 
surgery recommendations largely are based on studies on adults. For example, as long as the 
young adult remains in the obesogenic environment where he/she grew up, it is plausible to 
assume that the risk for weight gain post-RYGB is augmented, in which case it may be better 
to postpone surgery until the young adult is living an independent adult life with the 
capability to make own decisions on food choices etc. On the other hand, bariatric surgery 
with successful weight loss may increase the chances of the young adult finding a job given 
better psychosocial and physical functioning; this might be the missing link in the young 
adults’ journey to independence from his/her obesogenic childhood environment. 
Hypothetically, bariatric surgery in adolescence, before the BMI surge in young adulthood, 
may constitute a more appropriate timing 238. Recent studies reporting higher resolution of 
cardiovascular abnormalities in young vs older adolescents post-RYGB further promote such 
a hypothesis 330, and should be taken into account when developing guidelines for young 
adults with obesity.  
Moreover, our data align with data from well-known trials on adolescents, such as AMOS (as 
discussed in the introductory chapter) and the American FABS-5+ Study on n=74 13-to-21-
year-olds with a mean-baseline BMI of 58.5 (SD: 10.5) kg/m2 who displayed a 29.2% change 
in weight 8 years after surgery 331. Consequently, and importantly, we found promising 
results with similar weight loss outcomes in our real-life data as in trial-controlled 
environments on younger cohorts.   
 
7.4 METHODOLOGICAL CONSIDERATIONS  
Limitations in study design 
The main limitation of Studies I-II was the cross-sectional design, which did not allow for 
causal inferences. The lack of a control group in Study I limited the possibilities to relate the 
data to other patient groups; however, we overcame this in Study II. Moreover, we did not 
include variables on stigma, bullying and eating disorders when assessing mental health, 
which are common mediators/moderators in the association of obesity and mental distress. 
We had disappointing clinical experiences (unreliable findings) from using such 
questionnaires and therefore decided to exclude those variables. This may in turn have 
limited the comprehensive approach and the regression analysis of Study I.  
In Studies III-IV we used registry data, which may be associated with a number of 
limitations: Firstly, data entry may diverge between participating clinics due to differences in 
motivation and training of those who are responsible for data entry. Secondly, due to 
differences in economical compensation schemes in the Swedish healthcare system, follow-
up regimens may differ between clinics, and could cause biased results. This assumption 
could not be statistically tested, but the registry was visually inspected by the researchers with 
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this consideration in mind, and we found no obvious differences in percentages of young vs 
older adults between clinics, nor between high vs low volume centers. Moreover, well-known 
confounders of the outcomes, which were not included as variables in the registry, could not 
be adjusted for, and thus limited our analyses, possibly leading to underestimation or 
overestimation of odds ratios and relative risks.   
The nature of SOReg did not allow for detailed background data on the adverse events but the 
large numbers of data entries enabled us to study rare events. Since planning Study III, 
closure of mesenteric defects has been found to clearly reduce the risk of ileus after RYGB 
312, which consequently could not be accounted for in Study III. Concerning Studies III-IV 
stratification of results by more than one age group would have revealed more detailed 
information about the association between age and outcomes. However, we also analyzed age 
as a linear variable, and found weight loss to be linearly negatively associated with ageing 
(data not shown) further strengthening our results of age-dependent weight loss post-RYGB. 
Bias 
Bias refers to a systematic error whereby the calculated value might not be representative for 
the parameter that it is meant to estimate. Sampling bias refers to when individuals are 
excluded not completely at random; this results in a sample that is not representative of the 
population it is intended to estimate resulting in a biased estimated prevalence. Thereby, the 
external validity of the study may be impaired. In Study I we excluded certain patients 
(cognitive impairments and language barriers) beforehand, thereby risking a biased sample. 
Furthermore, the inclusion rate of 57% of treatment-seekers in Study II might be regarded as 
low whereby the external validity of the results might be affected. Likewise, certain 
individuals are underestimated in the Stockholm Public Health Cohort due to lower 
participation rates, such as non-native Swedes, who may bear an increased risk of mental 
distress as well as BMI. However, we found that the level of the main outcome for mental 
distress in Study II, GHQ-12, approximated the level of GHQ-12 in normative data on young 
adults (9.2 [SD: 5.5] vs 10.8 [SD: 5.8] in population controls), which increases the 
generalizability of the study 261 
Misinformation bias refers to bias due to measurement errors. Measurement errors which are 
the same in all included participants is referred to as non-differential misclassification and 
may lead to both under- and overestimations. For example, the reference values for Åstrand’s 
test (Study I) are based upon normal weight individuals while overweight individuals’ 
cardiorespiratory fitness is generally underestimated. Moreover, smoking and alcohol use 
(Studies I-IV) were repetitively found to be underestimated in self-reports, indicating another 
type of measurement error 332 333. Socioeconomic status (Studies I-II) is generally measured 
by income/educational level, or employment status. However, those measurements were not 
suitable since our cohort mainly consisted of students, whose disposable income may 
underestimate their socioeconomic status. Similarly, using educational level or employment 
grade as a measurement of socioeconomic status is not appropriate since some participants 
had not yet finished their education, or started working life. Given the well-known difficulties 
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with assessing socioeconomic status in the present age group, we decided to use economic 
strain as a proxy for economic status, which, as accounted for above, is by no means a 
complete measurement.  
Certain diseases in Study I may have been underdiagnosed or misdiagnosed, for example 
non-alcoholic fatty liver disease which necessitates liver biopsy for accurate diagnosis. To 
optimize the accuracy of the self-reports, a physician evaluated the responses together with 
the patient and against the patient’s health record. Moreover, we did not screen for 
malabsorption, which may account for some of the micronutritional deficiencies in Study I. 
Patients may have forgotten to fast the night before the blood samples, leading to an 
overestimation of mean values of glucose and lipids. We endeavored to overcome this error 
by checking the fasting status with every patient. 
Misclassification could differ between observation groups, due to the use of self-reports vs 
objective measurements of anthropometrics in Study II, called differential misclassification. 
Self-reports of weight and height (Studies II-IV) are known to underestimate body weight 
and overestimate body height, thereby risking underestimation of BMI 334.  
Another possible differential misclassification was found in Study IV regarding “impression 
management”, i.e. socially desired responses, which was previously found to differ between 
age groups 335.  
Attrition was a major risk factor for bias in Studies III-IV, since those with complete data are 
not necessarily representative for the baseline cohort. Notably, we found differences between 
missing and non-missing data in baseline variables, which warrant caution when interpreting 
our results. Given the higher drop-out rates in young vs older adults, results on weight loss 
and adverse events may have been skewed since young adults hypothetically attended only in 
cases of unacceptable adverse events, and thus may have caused an overestimation of adverse 
events in the young. We tried to overcome the risk for attrition bias either by using linear 
mixed models (Study III) or data imputation (Study III-IV) when analyzing weight loss and 
adverse events, however these statistical methods are by no means complete in reducing the 
risk of attrition bias.  
Data/statistical limitations 
Historically, there has been a long-standing debate on whether Likert scales should be treated 
as categorical or continuous scales and accordingly be analyzed by parametric or non-
parametric statistics 336. In Studies I-II & IV we analyzed GHQ-12, HADS, EQ5D and SF-36 
as continuous variables since these questionnaires may be treated as collections of several 
items which together produce, at least empirically, interval data which approximate 
continuous data 336 337. In Study IV we performed the non-parametric equivalent and found 
that the results did not differ materially from the results of parametric tests. 
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Unfortunately, certain baseline variables such as smoking were not mandatory in SOReg. 
Therefore, we could not include these as covariates in the completer’s analyses without 
risking the loss of more values and thus low statistical power. 
Frequency matching in Studies III-IV resulted in interpretation problems due to the large 
number of drop-outs, particularly in Study IV as about one third of participants lacked HRQL 
data and could thus not be included in the study. Consequently, matching was not properly 
valid for Study IV and the results must therefore be carefully evaluated. Ideally, matching on 
an individual basis could have partially overcome this problem. 
Study IV included a relatively large number of statistical tests (Tables 9-11), which 
inherently increase the risk of chance findings and thus type I errors.  
Strengths 
The main strength of this thesis was the focus on clinical aspects of young adults with obesity 
who are notorious for low participation and high drop-out rates in trials. Inclusion was 
possible via the cross-sectional design of Study I and the use of data from the Obesity Center, 
which specializes in young adults with obesity. In Studies III-IV, the use of high-quality 
registry data with 5-year follow-up enabled us to analyze close to 100% of Swedish 18-to-25-
year-olds who had undergone RYGB during the specific observation period, and thus 
provided us with real-life data as opposed to data in controlled environments/trials. 
The main methodological strength throughout Studies I-IV was the use of validated generic 
and disease-specific questionnaires that measured a wide array of mental health aspects. In 
Study II we successfully included population controls with obesity and severe obesity, which 
is rare in an international perspective.  
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8 CONCLUSION 
The overall conclusions of the present thesis are: 
 Treatment-seeking young adults (16-25 years) with obesity displayed indications of 
poor mental health, high frequencies of cardiovascular risk markers and 
micronutritional deficiencies. 
 
 Mental distress in treatment-seeking young adults (16-25 years) with obesity was 
independently associated with pain, low self-esteem, poor cardiorespiratory fitness 
and poor psychosocial functioning. 
 
 Treatment-seeking young adults (18-25 years) with obesity displayed approximately 
doubled RR for mental distress compared to normal weight population controls, and 
significantly more mental distress than population controls with class I obesity or 
severe obesity.  
 
 Young adults (18-25 years) displayed effective weight loss that was at least equal to 
older adults (26-74 years) but experienced more long-term adverse events and were 
less frequently followed-up, up to 5 years after RYGB, compared to older adults.  
 
 Young adults (18-25 years) displayed improved physical HRQL but no or weak 
changes in mental HRQL 5 years after RYGB compared to baseline levels.  
 
 Young adults (18-25 years) displayed smaller 5-year changes in physical role, general 
health, vitality, social functioning, physical component score and psychosocial 
functioning after RYGB than older (26-74 years) adults.  
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9 FUTURE RESEARCH 
To further improve the care of young adults with severe obesity, I propose the following 
areas to be addressed in future research: 
 Expansion of the significance of mental distress on weight loss outcomes and 
adherence to weight loss strategies.  
 
 Exploration of the etiology behind the present findings of higher rates of long-term 
adverse events in young vs older adults: Detailed data from patients’ health records 
may complement registry data to evaluate what symptoms are manifested behind the 
variable “serious adverse event” in the present thesis. Future studies need to address 
the high attrition rates in young adults if we are to draw more reliable conclusions on 
particularly adverse events than was possible in the present thesis.  
 
 Trials aimed at improving young adults’ follow-up rates post-RYGB and improved 
understanding of the significance of follow-up on outcomes. Digital follow-up has 
shown promising results in young adults if combined with face-to-face visits in 
behavioral weight management and should be evaluated also in bariatric medicine 
for patients who prefer non-physical meetings or live far away from the operating 
clinic 323 338. Standardized reporting of sensitivity analyses in longitudinal obesity 
research with large drop-outs may support the reader to interpret data in a less 
unbiased way than what is possible with completers´ analyses only.  
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Patienter inom åldersgruppen ”unga vuxna” (här 16-25 år) saknas generellt i klinisk 
fetmaforskning, trots att de tidiga vuxenåren utgör en klar riskperiod för att insjukna i fetma. 
Istället har vårdriktlinjer för unga vuxna baserats på forskning på barn och äldre 
åldersgrupper, vilket kan riskera att kliniska problem som är specifika för unga vuxna med 
fetma inte uppmärksammas i behandlingen. 
Syftet med den aktuella avhandlingen var att karaktärisera unga vuxna (16-25 år) som är 
vårdsökande för fetma, speciellt med avseende på psykisk ohälsa (karaktäriseringsstudier, 
studie I-II), samt att jämföra långtidseffekter av magsäckskirurgi mellan yngre (18-25 år) och 
äldre (≥26 år) vuxna med avseende på viktnedgång, komplikationer, uppföljningsgrad och 
livskvalitet (behandlingsstudier, studie III-IV).  
I studie I undersökte vi förekomst av fetmarelaterade följdsjukdomar, psykisk ohälsa, 
självkänsla, livsstilsfaktorer och livskvalitet; konditionsnivå och labbdata över näringsämnen 
samt metabola riskfaktorer bland 165 unga vuxna som sökte vård för fetma på en specialist-
klinik i Stockholm. I studie II jämförde vi enkätsvar över psykisk ohälsa, självmordsförsök, 
fysiska/psykosomatiska symtom och livskvalitet mellan 121 unga vuxna som sökte vård på 
samma fetmaklinik som i studie I, med data från individer som besvarat en regelbundet 
återkommande folkhälsoundersökning (Folkhälsoenkäten). I studie III-IV jämförde vi unga 
(18-25 år) och äldre (≥26 år) vuxna i det närmast heltäckande fetmakirurgiregistret 
(Scandinavian Obesity Surgery Registry) med avseende på viktnedgång, komplikationer, 
uppföljningsgrad och livskvalitet upp till fem år efter magsäckskirurgi. 
I studie I fann vi indikationer på att unga vuxna som söker fetmabehandling har höga nivåer 
av psykiska hälsoproblem och riskmarkörer för framtida hjärt-kärlsjukdom samt generella 
vitaminbrister. I studie II fann vi en nästan fördubblad risk för psykisk ohälsa, 
självmordsförsök, psykosomatiska symtom och låg livskvalitet bland unga som är 
vårdsökande för fetma jämfört med normalviktiga individer som besvarat Folkhälsoenkäten. I 
studie III fann vi att unga vuxna uppvisade en statistiskt säkerställd större viktnedgång fem år 
efter magsäckskirurgi jämfört med äldre vuxna (31.8% vs 28.2% viktnedgång). Dock var 
risken för allvarliga kirurgiska komplikationer dubbelt så hög bland de yngre jämfört med de 
äldre patienterna 2-5 år efter magsäckskirurgi (14.1% vs 6.9%), och uppföljningsfrekvensen 
var upp till nästan hälften så komplett i den yngre jämfört med den äldre gruppen under hela 
observationsperioden. Både yngre och äldre patienter hade fått en påtagligt förhöjd fysisk 
livskvalitet upp till fem år efter magsäckskirurgin, och förbättringen var störst i den äldre 
gruppen. Dock noterades ingen kliniskt relevant förbättring i mental livskvalitet i någondera 
av åldersgrupperna.  
Avhandlingen diskuterar de aktuella resultaten i en klinisk kontext såsom hur hög 
samsjuklighet mellan fetma och psykisk ohälsa bland unga vuxna kan hanteras i den kliniska 
vardagen samt kring magsäckskirurgins för- och nackdelar givet de psykosociala 
omständigheter som karaktäriserar de tidiga vuxenåren.  
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